UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~June 3130, 2024

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-56155

CRYOMASS TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Nevada		82-5051728
(State of incorporation)		(IRS Employer Identification No.)

1001 Bannock Street, Suite 612, Denver, CO		80204
(Address of principal executive offices)		(Zip Code)

303-416-7208

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No

As of ~~June~~August 2613, 2024 the registrant had ~~234~~235,~~634~~284,877 shares of its common stock, par value $0.001 per share, outstanding.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology.

The identification in this report of factors that may affect our future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Factors that could cause our actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to:

● Trends affecting our financial condition, results of operations or future prospects, including the impact of COVID-19 or other pandemics;

●

Our business and growth strategies;

●

Our financing plans and forecasts;

●

The factors that we expect to contribute to our success and our ability to be successful in the future;

●

Our business model and strategy for realizing positive results as sales increase;

●

Competition, including our ability to respond to such competition and its expectations regarding continued competition in the market in which we compete;

●

Our ability to meet our projected operating expenditures and the costs associated with development of new projects;

●

The impact of new accounting pronouncements on our financial statements;

●

Whether our cash flows from operating activities will be sufficient to meet our operating expenditures;

●

Our market risk exposure and efforts to minimize risk;

●

Regulations, including tax law and practice, federal and state laws governing the cannabis and cannabinoid industries, and tariff legislation;

●

Our overall outlook including all statements under Management’s Discussion and Analysis of Financial Condition and Results of Operations;

●

That estimates and assumptions made in the preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) may differ from actual results; and

●

Our expectations as to future financial performance, cash and expense levels and liquidity sources.

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance. A more detailed description of risk factors that may affect our operating results can be found in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q and Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on June 13, 2024, and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023	1
	Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023	1
	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2024 and 2023	2
	Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2024 and 2023	2
	Condensed Consolidated Statements of Shareholders’ Equity (Deficit) (Unaudited) for the Three Months Ended March 31, 2024 and 2023	3
	Condensed Consolidated Statements of Shareholders’ Equity (Deficit) (Unaudited) for the Three and Six Months Ended June 30, 2024 and 2023	3
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2024 and 2023	4
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2024 and 2023	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2223
Item 4.	Controls and Procedures	2223
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	2526
Item 1A.	Risk Factors	2526
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	2526
Item 3.	Defaults Upon Senior Securities	2526
Item 4.	Mine Safety Disclosures	2526
Item 5.	Other Information	2526
Item 6.	Exhibits	2627
Signatures		2728

CRYOMASS TECHNOLOGIES INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2024 (unaudited)			December 31, 2023
	June 30, 2024 (unaudited)			December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	23497,~~922~~900		$	49,224
Accounts receivable, net		86,~~852~~189			8,552
Prepaid expenses		7529,~~304~~108			94,746
Total current assets		~~108~~533,~~078~~197			152,522
Property and equipment, net		~~709~~696,~~996~~919			723,072
Intangible assets, net		7962,~~810~~708			96,912
Total assets	$	~~897~~1,~~884~~292,824		$	972,506
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued expenses	$	23,~~871~~329,~~563~~064		$	2,236,462
Deferred revenue, current		~~321~~481,250			20,000
Notes payable, current, net of discount		245,600			237,500
Deferred revenue, current – related party		80,000			-
Total current liabilities		3,438,413			2,493,962
Notes payable, current, net of discount		-			237,500
Deferred revenue, long term		70,000			75,000
Notes payable, current, net of discount – related party		2,639,577			-
Notes payable, net of discount		608,315			597,381
Total current liabilities		6,529,891			2,493,962
Notes payable, net of discount – related party		2,553,084			2,470,405
Deferred revenue, long term		65,000			75,000
Contingent royalty liability		2,546,000			1,185,000
Notes payable, net of discount		565,243			597,381
Total liabilities		9,215,812			6,821,748
Notes payable, net of discount – related party		-			2,470,405
Contingent royalty liability		2,590,000			1,185,000
Total liabilities		9,750,134			6,821,748
Commitments and contingencies (Note 12)
Shareholders’ equity (deficit):
Preferred stock, $0.001 par value, 100,000 shares authorized, no shares issued and outstanding respectively		-			-
Preferred stock, $0.001 par value, 100,000 shares authorized, no shares issued and outstanding, respectively		-			-
Common stock, $0.001 par value, 500,000,000 shares authorized, 211,037,383 and 202,651,205 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		211,038			210,033
Common stock, $0.001 par value, 500,000,000 shares authorized, 235,284,877 and 210,032,401 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		235,286			210,033
Additional paid-in capital		4547,~~992~~448,~~759~~856			45,907,981
Accumulated deficit		(5456,~~521~~141,~~725~~452	)		(51,967,256	)
Total shareholders’ equity (deficit)		(8,~~317~~457,~~928~~310	)		(5,849,242	)
Total liabilities and shareholders’ equity (deficit)	$	~~897~~1,~~884~~292,824		$	972,506

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRYOMASS TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Revenues	$	513,~~300~~889		$	-		$	19,189		$	-
Cost of goods sold		-			-			-			-
Gross profit		513,~~300~~889			-			19,189			-
Operating expenses:
Personnel costs		~~644~~561,~~003~~600			~~768~~723,~~266~~455			1,205,602			1,491,720
General and administrative		~~265~~254,~~588~~848			~~339~~446,~~895~~149			520,436			786,045
Legal and professional fees		~~117~~264,~~003~~135			~~298~~104,~~742~~497			381,139			403,239
Depreciation and amortization expense		30,179			~~124~~144,~~529~~336			60,358			268,865
Research and development		-			~~123~~13,238			-			13,361
Total operating expenses		1,056,773			1,531,555
Loss on impairment of intangible assets		-			3,653,043			-			3,653,043
Loss from operations		(1,051,473	)		(1,531,555	)
Loss on impairment of goodwill		-			1,190,000			-			1,190,000
Other income (expenses):
Total operating expenses		1,110,762			6,274,718			2,167,535			7,806,273
Interest expense, net		(158,634	)		(53,661	)
Loss from operations		(1,096,873	)		(6,274,718	)		(2,148,346	)		(7,806,273	)
Gain / (loss) on foreign exchange		16,638			(13,310	)
Other income (expenses):
Loss on contingent royalty liability		(1,361,000	)		-
Interest expense – net		(149,787	)		(82,602	)		(308,421	)		(136,263	)
Total other expenses		(1,502,996	)		(66,971	)
Gain / (loss) on foreign exchange		9,830			(4,486	)		26,468			(17,796	)
Net loss before taxes		(2,554,469	)		(1,598,526	)
Loss on contingent royalty liability		(44,000	)		-			(1,405,000	)		-
Income taxes		-			-
Loss on extinguishment of debt		(338,897	)		-			(338,897	)		-
Net loss		(2,554,469	)		(1,598,526	)
Total other expenses		(522,854	)		(87,088	)		(2,025,850	)		(154,059	)
Net loss per common share:
Net loss before taxes		(1,619,727	)		(6,361,806	)		(4,174,196	)		(7,960,332	)
Loss per common share – basic and diluted	$	(0.01	)	$	(0.01	)
Income taxes		-			-			-			-
Weighted average common shares outstanding—basic and diluted		203,523,079			204,021,504
Net loss		(1,619,727	)		(6,361,806	)		(4,174,196	)		(7,960,332	)
Net loss per common share:
Loss per common share – basic and diluted	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.04	)
Weighted average common shares outstanding—basic and diluted		220,446,289			205,232,785			215,196,374			204,881,096

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRYOMASS TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

	Common Stock				Additional Paid-In			Common Stock to			Accumulated			Total Shareholders’ Equity
	Shares		Amount		Capital			Be Issued			Deficit			(Deficit)
Balance at December 31, 2022		202,651,205	$	202,652	$	43,163,579		$	219,765		$	(39,011,528	)	$	4,574,468
Common stock issued for prior period services		62,500		62		21,813			(21,875	)		-			-
Common stock issued for current period services		187,500		188		65,438			-			-			65,626
Common stock issued for vested RSUs for prior period services		1,100,000		1,100		196,790			(197,890	)		-			-
Common stock issued for vested RSUs for current period services		777,932		778		49,222			-			-			50,000
Stock-based compensation for vested RSUs for current period services		-		-		62,972			-			-			62,972
Net loss		-		-		-			-			(1,598,526	)		(1,598,526	)
Balance at March 31, 2023		204,779,137	$	204,780	$	43,559,814		$	-		$	(40,610,054	)	$	3,154,540
Common stock issued for current period services		187,500		187		19,925			-			-			20,112
Common stock issued for vested RSUs for current period services		802,000		802		79,118			-			-			79,920
Stock-based compensation for vested RSUs for current period services		-		-		173,631			-			-			173,631
Warrants issued in conjunction with notes payable		-		-		179,026			-			-			179,026
Net loss		-		-		-			-			(6,361,806	)		(6,361,806	)
Balance at June 30, 2023		205,768,637	$	205,769	$	44,011,514		$	-		$	(46,971,860	)	$	(2,754,577	)
Balance at December 31, 2023		210,032,401	$	210,033	$	45,907,981		$	-		$	(51,967,256	)	$	(5,849,242	)
Common stock issued for vested RSUs for prior period services		1,004,982		1,005		(1,005	)		-			-			-
Stock options issued for current period services		-		-		57,557			-			-			57,557
Stock-based compensation for vested RSUs for current period services		-		-		28,226			-			-			28,226
Net loss		-		-		-			-			(2,554,469	)		(2,554,469	)
Balance at March 31, 2024		211,037,383	$	211,038	$	45,992,759		$	-		$	(54,521,725	)	$	(8,317,928	)
Common stock and warrants issued for prior period services		1,250,000		1,250		48,750			-			-			50,000
Stock options issued for current period services		-		-		18,915			-			-			18,915
Stock-based compensation for vested RSUs for current period services		-		-		25,000			-			-			25,000
Share issuance from sale of common stock and warrants		13,225,000		13,225		694,926			-			-			708,151
Share issuance from debt cancellation		9,772,494		9,773		668,506			-			-			678,279
Net loss		-		-		-			-			(1,619,727	)		(1,619,727	)
Balance at June 30, 2024		235,284,877	$	235,286	$	47,448,856		$	-		$	(56,141,452	)	$	(8,457,310	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRYOMASS TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended March 31,
	For the Six Months Ended June 30,
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(24,~~554~~174,~~469~~196	)	$	(17,~~598~~960,~~526~~332	)
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:
Amortization of debt discount (premium)		3373,~~785~~752			-13,036
Depreciation and amortization expense		3060,~~179~~358			~~124~~268,~~529~~865
Loss (gain) on foreign exchange related to notes payable		(179,~~933~~776	)		-1,413
Loss on contingent royalty liability		1,361,000			-
Loss on impairment of goodwill		-			1,190,000
Principal in-kind interest accrued		85,860			-
Loss on impairment of intangible assets		-			3,653,043
Common stock issued for vested RSUs for prior period services		-			50,000
Loss on extinguishment of debt		338,897			-
Stock-based compensation for vested RSUs for current period services		28,226			62,972
Loss on contingent royalty liability		1,405,000			-
Stock options issued for current period services		57,557			-
Payment in-kind interest accrued		174,939			-
Common stock issued for current period services		-			65,626
Common stock issued for vested RSUs for current period services		-			129,920
Stock-based compensation for vested RSUs for current period services		53,226			236,603
Stock options issued for current period services		76,472			-
Common stock and warrants issued for prior period services		50,000			-
Common stock issued for current period services		-			85,738
Change in operating assets and liabilities:
Accounts receivable, net		~~(300~~2,363	)		-
Prepaid expenses		1965,~~442~~638			35(11,~~877~~700	)
Accounts payable and accrued expenses		~~635~~1,~~101~~092,602			~~(78~~55,~~821~~964	)
Deferred revenue		~~296~~531,250			-
Net cash used in operating activities		(25259,~~302~~475	)		(12,~~338~~337,~~343~~450	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible assets		-			(1349,~~736~~236	)
Net cash used in investing activities		-			(1349,~~736~~236	)
CASH FLOWS FROM FINANCING ACTIVITIES:
None		-			-
Proceeds from notes payable		-			686,896
Net cash used in financing activities		-			-
Proceeds from issuance of common stock and warrants		708,151			-
Net increase (decrease) in cash and cash equivalents		(25,302	)		(1,352,079	)
Net cash used in financing activities		708,151			686,896
Net increase (decrease) in cash and cash equivalents		448,676			(1,699,790	)
Cash and cash equivalents at beginning of period		49,224			2,016,057
Cash and cash equivalents at end of period	$	23497,~~922~~900		$	~~663~~316,~~978~~267
Supplemental disclosure of non-cash investing activities:
Purchase of property and equipment on credit	$	-			~~(221~~246,577	)
Supplemental disclosure of non-cash financing activities:
Debt discount recognized from warrants issued in conjunction with notes payable		-			179,026
Stock issued for cancellation of debt		678,279			-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of the Business

Cryomass Technologies Inc. (the “Company”) develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, Cryomass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).

The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this report.

Cryomass Technologies Inc. is the parent company to wholly-owned subsidiaries Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada.

On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The acquired assets included the patented cryogenic process titled “System and method for cryogenic separation of plant material” (US patent #10,864,525) for the reduction of biomass and efficient isolation, collection and preservation of delicate resin glands (trichomes) of harvested of hemp and cannabis, and potentially other high value trichome-rich plants.

In September 2021, we were granted an additional patent for our process from the Chinese Intellectual Property Office. In April 2022, we were granted another patent #3,064,896 from the Canadian Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and other international jurisdictions.

The first functional commercial unit, known as a CryoSift Separator™, has been installed at the premises of an operating partner, pursuant to a license and lease arrangement, in California.

2. Going Concern Uncertainty, Financial Conditions and Management’s Plans

The Company believes that there is substantial doubt about the Company’s ability to continue as a going concern. The Company believes that its available cash balance as of the date of this filing will not be sufficient to fund its anticipated level of operations for at least the next twelve months. The Company believes that, at the present time, its ability to continue operations depends on cash expected to be available from planned equipment sales and royalty payments in connection with future revenue generation, or possibly from debt or equity investments, to fund its anticipated level of operations for at least the next twelve months. As of ~~March~~June 3130, 2024, the Company had a working deficit of $35,~~330~~996,~~335~~694 and cash balance of $23497,~~922~~900. The Company estimates that it needs approximately $3,200,000 to cover overhead costs and has capital expenditure requirements of up to $3,125,000, based on the current pipeline of customer activity. The Company believes that the Company will continue to incur losses for the immediate future. The Company expects to finance future cash needs from the results of operations and additional financing until the Company can achieve profitability and positive cash flows from operating activities from, for example, our recently signed equipment purchase and revenue sharing agreements. Since the operating expenses of the unit are required to be covered by licensee and not the Company, the royalty payment would be free cash flow which could be used to cover operating expenses. However, there can be no assurance that the Company will receive sufficient operating cash flow from this agreement or that we will be able to attract the necessary financing.

The continuation of our Company as a going concern is dependent upon the continued financial support from our shareholders, the ability of our Company to obtain necessary equity, debt or other financing to continue operations, and ultimately the attainment of profitable operations. For the ~~three~~six months ended ~~March~~June 3130, 2024, our Company used $25259,~~302~~475 of cash for operating activities, incurred a net loss of $24,~~554~~174,~~469~~196 and has an accumulated deficit of $5456,~~521~~141,~~725~~ 452 since inception.

Our financial statements for the three and six months ended ~~March~~June 3130, 2024 have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty.

3. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying ~~condensedconsolidated~~condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles. The ~~Thecondensed~~condensed consolidated financial statements include the accounts of the Cryomass Technologies Inc., Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada. All significant intercompany balances and transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturities of three months or less at the time of issuance to be cash equivalents.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. Subsequently, the FASB issued several other updates related to revenue recognition (collectively with ASU 2014-09, the “new revenue standards” or “ASC 606”). In June 2020, the FASB issued ASU No. 2020-05, Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, further delaying the effective date for Topic 606 to fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020.

Pursuant to ASC 606, entities recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to each performance obligation, and (v) recognize revenue when or as each performance obligation is satisfied (i.e., either point in time or over time).

The promised goods or services in the Company’s arrangements typically consist of (1) a license, including rights to the Company’s intellectual property; or / and (2) an obligation to make available for use equipment uniquely suited to apply the intellectual property to customers.

Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract. For performance obligations which consist of products, shipping and distribution activities occur prior to the transfer of control of the Company’s products and are considered activities to fulfill the Company’s promise to deliver goods to the customers.

The Company estimates the transaction price based on the amount expected to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.

Customer prepayments are recorded as contract liabilities (deferred revenue), which shall be subsequently recognized as revenue upon satisfaction of the underlying performance obligations over the life of the contract. The portion of the liabilities that is expected to be recognized as revenue during the succeeding twelve-month period are recorded in Deferred Revenue and the remaining portion is recorded in Deferred Revenue, long term on the accompanying balance sheets at the end of each reporting period.

Expenses

Operating Expenses

Operating expenses encompass personnel costs, research and development expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related to the property and equipment and intangibles acquired through the implementation of internal -use software. Personnel costs consist primarily of consulting expense and administrative salaries and wages. General and administrative expenses are comprised of travel expenses, accounting expenses, stock-based compensation, and board fees. Professional services are principally comprised of outside legal and professional fees.

Other Expense, net

Other income (~~Expenses~~expenses) consisted of interest expense, net gain (loss) on foreign exchange and loss on extinguishment of debt.

Stock-Based Compensation

The fair value of restricted stock units (“RSUs”) granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are recorded in general and administrative expenses in the consolidated statements of operations.

Property and Equipment, net

Purchase of property and equipment are recorded at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the condensed consolidated statements of operations. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:

		Estimated Useful Life
Machinery and equipment		15 years

Goodwill and Intangible Assets

Goodwill represents the excess of the purchase price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business combination.

Indefinite-lived intangible assets established in connection with business combinations consist of in-process research and development and internal-use software. Intangible assets with indefinite lives are recorded at their estimated fair value at the date of acquisition. Once in-process research and development is placed in service, it will be amortized over the estimated useful life. Internal-use software costs recognized as an intangible asset relates to capitalizable costs of computer software obtained for internal-use as defined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350-40-30-1. All other internal-use software costs are expensed as incurred by the Company. Amortization is recorded straight-line over the estimated useful life of the software. The software has a useful life of 26 months with amortization beginning on April 1, 2023.

Intangible assets with finite lives are recorded at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method. Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table below:

		Estimated Useful Life
Patent		120 Months
In-process research and development		104 Months
Internal-use software		26 Months

Impairment of Goodwill and Intangible Assets

Goodwill

Goodwill is not amortized, but instead is tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances.

We account for the impairment of goodwill under the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” and FASB Accounting Standards Codification (ASC) 350-20-35, Intangibles – Goodwill and Other – Goodwill.

The Company performs impairment testing for goodwill by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value.

Due to delays in implementing the Company’s business model of its cryogenic process, management fully impaired goodwill during 2023.

Indefinite-Lived Intangible Assets and Intangible Assets Subject to Amortization

Indefinite-lived intangible assets are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances.

We account for the impairment of indefinite-lived intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35, Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill. Following this guidance, the Company compares the estimated fair value of the indefinite-lived intangible assets to its carrying value. If the carrying value exceeds the fair value, the Company recognizes impairment equal to that excess.

We account for the impairment of intangible assets subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Property, Plant, and Equipment. Following this guidance, the Company compares the estimated fair value of the intangible assets subject to amortization to its carrying value. If the carrying value exceeds the fair value, the Company recognizes impairment equal to that excess.

Due to delays in implementing the Company’s business model of its cryogenic process, management fully impaired all related identifiable intangible assets including a patent and in-process research & development in 2023. Internal -use software was not impaired as of June ~~March 31~~30, 2024.

Leases

We account for our leases under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the condensed consolidated balance ~~sheet~~sheets as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or our incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For finance leases, interest on the lease liability and the amortization of the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred.

In calculating the right -of -use asset and lease liability, we have elected to combine lease and non-lease components. We exclude short-term leases having an initial term of 12 months or less from the new guidance as an accounting policy election, and recognize rent expense on a straight-line basis over the lease term.

Income Taxes

The Company uses the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is likely that the deferred tax assets will not be realized. We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the consolidated financial statements.

Fair Value Measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

	●	Level 1 — Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

	●	Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The carrying values reported in the consolidated balance sheets for cash, accounts receivable, prepaid expenses, accounts payable, and notes payable approximate fair values because of the immediate or short-term maturities of these financial instruments.

Between April and November 2023, the Company issued warrants in conjunction with promissory notes (the “Promissory Notes”) and common stock subscription agreements (the “Common Stock Subscription Agreements”) to investors as part of a capital raising effort The Company has determined that the Warrants are classified as equity and are initially measured at fair value. The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance. As the fair value of the Promissory Notes at the issuance date is less than the cash proceeds received, a debt discount on the Promissory Notes was also recorded. The debt discount will be amortized over the lives of the Promissory Notes using the effective interest method.

On September 15, 2022, the Company entered into a $2,000,000 Loan Agreement and Unsecured Promissory Note with CRYM Co-Invest (“CRYM Co-Invest”), which accrued interest at 12% per annum, payable quarterly. On December 31, 2023, the parties amended and restated the agreement which includes an additional loan amount of $135,000, disbursed on December 22, 2023. The total principal is $2,289,590, which includes ~~principal~~ payment-in-kind interest and accrues regular interest at an amended rate of 15% annually. The Company is obligated to repay the principal and all remaining accrued interest in full by April 1, 2025. A discounted cash flow analysis was used to determine the fair value of the debt. As an inducement, the Company also issued four tranches of common stock purchase warrants to CRYM Co-Invest that are exercisable up until February 8, 2029 and include a cashless exercise option. The total number of warrant shares issued was 20,000,000 (each tranche for 5,000,000 shares, exercisable at $0.25, $0.50, $0.75 and $1.00, per share, respectively). The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance. The Company also included a sale and purchase commitment option feature where CRYM Co-Invest has agreed to direct its affiliates to purchase up to five (5) units of the Company’s equipment for $1,200,000 each. Along with the sale and purchase commitment option, if the Company identifies a suitable lessee to rent the equipment from the affiliate and enter into an equipment rental agreement, then CRYM Co-Invest and the Company will each receive 50% of a monthly processing fee for the term of the equipment rental. Lastly, the amended ~~agreement~~ agreement also includes a net revenue sharing commitment feature that begins after the first equipment purchase by the lender’s affiliate, whereby the Company will remit 10% of the Company’s quarterly net revenue that is generated through non-affiliated rental and non-affiliated sales income. With respect to the measurement of the contingent liability for future net revenue royalty payments, management has measured this based on the best estimate of the expected future liability as of ~~March~~June 3130, 2024.

Net Loss per Share

The Company follows ASC 260, Earnings Per Share, which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the income statement for all entities with complex capital structures. Net earnings or loss per share is computed by dividing net income or loss by the weighted-average ~~number~~ number of common shares outstanding during the period, excluding shares subject to redemption or forfeiture. The Company presents basic and diluted net earnings or loss per share. Diluted net earnings or loss per share reflect the actual weighted average of common shares issued and outstanding during the period, adjusted for potentially dilutive securities outstanding. Potentially dilutive securities are ~~excluded~~ excluded from the computation of the diluted net loss per share if their inclusion would be anti-dilutive. As of June 30, 2024, the Company has 19,598,295 unexercised options and 80,082,322 unexercised warrants outstanding. Diluted net loss per share is the same as basic net loss per share for each period.

4. Revenue

On September 23, 2023, the Company recognized a deferred revenue balance of $100,000 on receipt of the upfront fee associated with the delivery of one complete unit of processing equipment and patent license to RubberRock Inc, as defined in the territory license fee section of our licensing agreement. ~~This amount will be amortized straight-line over the 5-year contract term.~~ As such, the Company recognized $5,000 of revenue in Q1Q2 2024. As of ~~March~~June 3130, 2024, $100,000 of the territory license fee was paid and $9085,000 remained in deferred revenue. On July 22, 2024, the Company gave notice to terminate its agreement with RubberRock, due to non-compliance with material terms of the Patent License and Equipment Rental Agreement.

The Company additionally recognized $~~300~~8,890 and $9,190 of royalty revenue from its contract with RubberRock Inc. induring Q1the three and six months ended June 30, 2024, respectively.

5. Property and Equipment, Net

Property and equipment, net, of $~~709~~696,~~996~~919 and $723,072 as of ~~March~~June 3130, 2024 and December 31, 2023, respectively, consisted entirely of machinery and equipment.

	March 31, 2024			December 31, 2023
	June 30, 2024			December 31, 2023
Machinery and equipment		777,833			777,833
Less: Accumulated depreciation		(6780,~~837~~914	)		(54,761	)
	$	~~709~~696,~~996~~919		$	723,072

Depreciation expense for the three and six months ended ~~March~~ 31June 30, 2024 was $13,077 and ~~2023~~$26,153, respectively. Depreciation expense for the three and six months ended June 30, 2023 was $13,077 and 10$23,~~130~~207, respectively.

6. Goodwill and Intangible Assets

The carrying value of goodwill was $0 as of ~~March 31~~June 30, 2024 and December 31, 2023. We fully impaired goodwill due to delays in implementing our business model, resulting in a $1,190,000 impairment charge in 2023. No additional goodwill has been recognized.

The following tables summarize information relating to the Company’s identifiable intangible assets as of ~~March~~June 3130, 2024 and December 31, 2023:

March 31, 2024

June 30, 2024

Estimated

Gross

Accumulated

Carrying

Useful Life

Amount

Amortization

Impairment

Value

Amortized

Internal-use software

26 months

148,219

(6885,~~409~~511

)

7962,~~810~~708

Total identifiable intangible assets

148,219

(6885,~~409~~511

)

7962,~~810~~708

	December 31, 2023
	Estimated	Gross		Accumulated						Carrying
	Useful Life	Amount		Amortization			Impairment			Value
Amortized
Patent	120 months	$	873,263	$	(174,653	)	$	(698,610	)	$	-
Internal-use software	26 months		148,219		(51,307	)		-			96,912
In-process research and development	104 months		3,209,000		(254,567	)		(2,954,433	)		-
Total identifiable intangible assets		$	4,230,482	$	(480,527	)	$	(3,653,043	)	$	96,912

Amortization expense was $17,102 and $~~114~~34,~~399~~ 204 for the three and six months ended ~~March~~June 3130, 2024, respectively. Amortization expense was $131,260 and $245,659 for the three and six months ended June 30, 2023, respectively.

Years ending December 31,	Amount
2024 (remainder of year)		5134,~~309~~206
2025		28,~~501~~502
		79,810
		62,708

7. Deferred Revenue

On August 18, 2023, we signed a license agreement with California-based RubberRock Inc and its affiliates (“RubberRock” or the “Licensee”). Under the agreement, RubberRock obtained from us a license to use and rent one unit of our equipment under certain rights for the use of the licensed patent solely in connection with the equipment and solely in California. We retain title to and have access to the equipment at all times. The duration of the agreement iswas five years from August 18, 2023. We subsequently amended the agreement on January 9, 2024 and on February 28, 2024. On July 22, 2024, the Company gave notice to terminate its agreement with RubberRock, due to non-compliance with material terms of the Patent License and Equipment Rental Agreement.

Under the terms of the amended agreement, which are further detailed below, RubberRock agreed to license the patented process and deploy a Unit in exchange for a territory license fee (the “Territory License Fee”) of $100,000 payable in one or more payments as determined by the Company. The Equipment was delivered to the agreed -upon RubberRock location on September 13, 2023 and RubberRock paid $100,000 of the total Territory License Fee on September 25, 2023.

In addition to the Territory License Fee, RubberRock ~~will~~had the obligation to pay Cryomass monthly royalties.

Subsequent to the commencement of the RubberRock agreement, our Chief Executive Officer, Christian Noel, joined the board of directors of RubberRock at the end of September 2023, which created a related party disclosure requirement. Mr. Noel left the board of RubberRock in January, 2024.

In the third quarter of 2023, we determined that the $100,000 of territory license fees we received did not yet meet the criteria for revenue recognition and therefore was recorded as deferred revenue. As this amount is recognized as revenue over the five-year life of the contract, we recognized $5,000 of revenue in the first quarter of 2024. As of ~~March~~June 3130, 2024, we had total deferred revenue, current and long term of $20,000 and $7065,000, respectively, related to this agreement. On July 22, 2024, the Company gave notice to terminate its agreement with RubberRock, due to non-compliance with material terms of the Patent License and Equipment Rental Agreement.

On May 9, 2024, Cryomass entered into an Equipment Purchase ~~And~~and Sale Agreement wherein CRYM Co-Invest Unit #2 LLP (“CRYM2”), a special purpose vehicle created for the purpose, agreed to purchase one CryoSift Separator Unit for $1.2 million. In turn, CRYM2 entered into a lease agreement with a wholly-owned US subsidiary of Leef Brands Inc of Vancouver, Canada to lease the CryoSift Separator for three years with one three-year ~~options~~option to renew.

In the first ~~quarter~~half of 2024, we determined that the $~~301~~461,250 of payments we received did not yet meet the criteria for revenue recognition and therefore was recorded as deferred revenue. As of ~~March~~June 3130, 2024, we had total deferred revenue, current, of $~~301~~461,250, related to this agreement.

On June 25, 2024, we received $80,000 related to a territory license fee from a related party that did not yet meet the criteria for revenue recognition and therefore was recorded as deferred revenue. As of June 30, 2024, we had total deferred revenue, current, of $80,000, related to this transaction.

8. Notes Payable

Between April and November 2023, the Company issued Promissory Notes to investors as part of a capital raising effort. The Promissory Notes issued have a total principal amount of $1,240,755, or $1,255,206 net of foreign currency adjustments, and bear interest of 12%. Of the $1,240,755 received in Promissory Notes with warrants, $175,000 of the proceeds are from related parties (net of initial debt discount of $54,128), which is further detailed in Note 9. The Promissory Notes have maturities between 24 and 32 months after issuance, at which point repayment is due in full. In conjunction with the Promissory Notes, the Company also issued Warrants to purchase common shares of the Company (the “Common Shares”) to the same investors. The Company issued 3,381,300 warrants with an exercise price of $0.25 and 2,032,500 with an exercise price of $0.09. The Warrants are exercisable for four years from the issuance date. The Company has determined that the Warrants are classified as equity and are initially measured at fair value. The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.13 for April subscription agreements, one of which is for Simon Langelier, $0.09 for May subscription agreements, $0.12 for the June subscription agreement, $0.14 for the July subscription agreement, $0.09 for the October subscription agreement, $0.08 for the November subscription agreement), term (4 years), historical volatility (152-154%), and risk-free rate (3.8% for April subscription agreements, 3.6% and 3.7% for May subscription agreements for Mario Gobbo and a private investor, respectively, 4.0% for a June subscription agreement for Health Diplomats Pte Ltd, 4.2% for a July subscription agreement, 5.0% for an October subscription agreement, 4.6% for a November subscription agreement). The grant date fair value of the Warrants was $351,054. The fair value of the Promissory Notes was $889,701. As the fair value of the Promissory Notes at the issuance date is less than the cash proceeds received, a debt discount on the Promissory Notes of $351,054 was also recorded. As of ~~March~~June 3130, 2024, the carrying value of the Promissory Notes was $~~992~~704,~~822~~149, net of discount, of which $~~853~~565,~~916~~243 relates to non-related parties, and the interest accrued was $~~112~~119,~~247~~625.

On April 23, 2024, the Company entered into an agreement with one of its debtors to convert the outstanding net book value of the principal and interest on the note payable of $267,176 into 7,647,494 shares of the Company’s common stock at $0.04 per share and 7,647,494 warrants to purchase shares of the Company’s common stock at an exercise price of $0.07 per share.

On June 12, 2024, the Company entered into an agreement with one of its debtors to convert the outstanding net book value of the principal and interest on the note payable of $71,906 into 2,125,000 shares of the Company’s common stock at $0.04 per share and 2,125,000 warrants to purchase shares of the Company’s common stock at an exercise price of $0.06 per share.

The table below discloses the aggregate amount of long-term borrowings maturing in each of the following years:

Years ending December 31,	Amount
2024	-	~~250,000~~
2025		~~812~~731,~~274~~048
2026		-
2027		-
2028		-
Total gross principal		1731,~~062,274~~048
(Less: debt discount, net of amortization)		(~~208~~165,~~358~~805	)
Carrying value as of March 31, 2024		853,916
Carrying value as of June 30, 2024		565,243

9. Related Party Transactions

On September 15, 2022, the Company entered into a loan agreement of $2,000,000 with CRYM Co-Invest LP, of which Alexander Massa, a 23.1% beneficial owner of the Company, has investment control. On December 31, 2023, the parties amended and restated the agreement, which includes an additional loan amount of $135,000, disbursed on December 22, 2023. The total principal is $2,289,590, which includes ~~principal~~ payment-in-kind interest and accrues regular interest at an amended rate of 15% annually. The Company is obligated to repay the principal and all remaining accrued interest in full by April 1, 2025. A discounted cash flow analysis was used to determine the fair value of the debt. As an inducement, the Company also issued four tranches of common stock purchase warrants to CRYM Co-Invest that are exercisable up until February 8, 2029 and include a cashless exercise option. The total number of warrant shares issued was 20,000,000 (each tranche for 5,000,000 shares, exercisable at $0.25, $0.50, $0.75 and $1.00, per share, respectively). The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.04), term (5 years), rounded annual volatility (150%), and risk-free rate (3.84%). The Company also included a sale and purchase commitment option feature where CRYM Co-Invest has agreed to direct its affiliates to purchase up to five (5) units of the Company’s equipment for $1,200,000 each. Along with the sale and purchase commitment option, if the Company identifies a suitable lessee to rent the equipment from the affiliate and enter into an equipment rental agreement, then CRYM Co-Invest and the Company will each receive 50% of a monthly processing fee for the term of the equipment rental. Lastly, the amended agreement also includes a net revenue sharing commitment feature that begins after the first equipment purchase by the lender’s affiliate, whereby the Company will remit 10% of the Company’s quarterly net revenue that is generated through non-affiliated rental and non-affiliated sales income. With respect to the measurement of the contingent liability for future net revenue royalty payments, management has measured this based on the best estimate of the expected future liability as of ~~March~~June 3130, 2024.

~~The~~During Q2 2023, the Company received $100,000, $50,000, and $25,000 from Simon Langelier, Health Diplomats Pte Ltd, and Mario Gobbo, respectively. Mr. Langelier and Mr. Gobbo are directors of the Company. Dr. Delon Human is also a director of the Company and is the President of Health Diplomats Pte Ltd. The notes mature on April 17, 2025, June 5, 2025 and May 2, 2025, respectively, and accrue interest at 12% per annum. In conjunction with the loans, the respective parties were issued warrants to purchase 454,500, 227,250, and 113,625 shares of common stock with an exercise price of $0.25 per share. The warrants expire on April 17, 2027, June 5, 2027 and May 2, 2027, respectively.

The table below discloses the aggregate amount of long-term borrowings from related parties maturing in each of the following years:

Years ending December 31,	Amount
2024		-
2025		2,~~550~~639,~~450~~529
2026		-
2027		-
2028		-
Total gross principal		2,~~550~~639,~~450~~529
Debt premium, net of amortization		3829,~~728~~046
(Less: debt discount, net of amortization)		(3628,~~094~~998	)
Carrying value as of March 31, 2024		2,553,084
Carrying value as of June 30, 2024		2,639,577

10. Shareholders’ Equity

From January to March 2023, the Company issued 62,500 shares of common stock for a total dollar value of $21,875 for prior period services, 187,500 shares of common stock for a total dollar value of $65,626 for current period services, 777,932 shares of common stock for a total dollar value of $50,000 for vested RSUs for current period services, and 1,100,000 shares of common stock for a total dollar value of $197,890 for vested RSUs for prior period services.

From April to June 2023, the Company issued 187,500 shares of common stock for current period services, as follows: 62,500 shares were issued at $0.091 per share for a total dollar value of $5,687, 62,500 shares were issued at $0.0909 per share for a total dollar value of $5,681, and 62,500 shares were issued at $0.1399 per share for a total dollar value of $8,744, all related to compensation to a consultant. The Company issued 802,000 shares of common stock for vested RSUs for current period services, as follows: 550,000 shares were issued at $0.098 per share for a total dollar value of $53,900, 187,000 shares were issued at $0.0995 per share for a total dollar value of $18,607, 10,000 shares were issued at $0.1088 per share for a total dollar value of $1,088, and 55,000 shares were issued at $0.115 per share for a total dollar value of $6,325, all relating to employee compensation.

From January to March 2024, the Company issued 1,004,982 shares of common stock for a total dollar value of $49,956 for vested RSUs for prior period services.

From April to June 2024, the Company issued 1,250,000 shares of common stock in conjunction with warrants for prior period services with a total dollar value of $50,000, 13,225,000 shares of common stock in conjunction with warrants related to capital raise efforts for a total dollar value of $708,151, and 9,772,494 shares of common stock in conjunction with warrants to cancel outstanding debt for a total dollar value of $678,279.

Restricted Stock Unit Awards

The Company adopted its 2019 Omnibus Stock Incentive Plan (the “2019 Plan”), which provides for the issuance of stock options, stock grants and RSUs to employees, directors and consultants. The primary purpose of the 2019 Plan was to enhance the ability to attract, motivate, and retain the services of qualified employees, officers and directors. Any RSUs granted under the 2019 Plan were at the discretion of the Compensation Committee of the Board of Directors. On January 10, 2022, the shareholders approved the 2022 Stock Incentive Plan which then replaced the 2019 Plan.

A summary of the Company’s RSU award activity for the three and six months ended ~~March~~June 3130, 2024 and 2023, respectively, is as follows:

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		2,185,210		$	0.20
Granted		-			-
Vested		(1,004,982	)		0.23
Forfeited		(68,500	)		0.13
Outstanding at March 31, 2024		1,111,728		$	0.18
Granted		-			-
Vested		-			-
Forfeited		-			-
Outstanding at June 30, 2024		1,111,728		$	0.18

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2022		1,453,857		$	0.30
Granted		2,760,660			0.17
Vested		(1,877,932	)		0.23
Forfeited		-			-
Outstanding at March 31, 2023		2,336,585		$	0.21
Granted		755,500			0.10
Vested		(802,000	)		0.12
Forfeited		-			-
Outstanding at June 30, 2023		2,290,085		$	0.21

The total fair value of RSUs vested during the three and six months ending ~~March~~June 3130, 2024 was $25,000 and $53,226, respectively. The total fair value of RSUs vested during the three and six months ending June 30, 2023, was $~~233~~79,~~889~~920 and $~~424~~327,~~640~~810, respectively. As As of ~~March~~June 3130, 2024 and 2023, there was $7752,957 and $~~303~~416,~~663~~205, respectively, of unrecognized stock-based compensation cost related to non-vested RSU’s, which is expected to be recognized over the remaining vesting period ending January 10, 2025.

Stock-based compensation expense relating to RSU’s was $2825,~~226~~000 and $~~112~~53,~~972~~226 for the three and six months ending ~~March~~June 3130, 2024, respectively. Stock-based compensation expense relating to RSU’s was $253,552 and ~~2023~~$366,523 for the three and six months ending June 30, 2023, respectively. Expenses for stock-based compensation are included on the accompanying condensed consolidated statements of operations in general and administrative expense.

Stock Option Awards

A summary of the Company’s stock option activity for the three and six months ended ~~March~~June 3130, 2024, and 2023, respectively, is as follows:

	Stock Option Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2023		11,513,214	$	0.17		7.3	$	1,962,017
Outstanding and exercisable at December 31, 2023		11,513,214	$	0.17		7.3	$	1,962,017
Granted		8,085,081		0.05		5.4		~~57,557~~-
Forfeited		-		-		-		-
Outstanding at March 31, 2024		19,598,295	$	0.12		6.4	$	2,019,574
Outstanding and exercisable at March 31, 2024		19,598,295	$	0.12		6.4	$	2,019,574
Granted		-		-		-		-
Forfeited		-		-		-		-
Outstanding and exercisable at June 30, 2024		19,598,295	$	0.12		6.1	$	2,038,489

	Stock Option Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2022		8,500,000	$	0.18		8.5	$	1,579,108
Outstanding and exercisable at December 31, 2022		8,500,000	$	0.18		8.5	$	1,579,108
Granted		-		-		-		-
Forfeited		-		-		-		-
Outstanding at March 31, 2023		8,500,000	$	0.18		8.0	$	1,579,108
Outstanding and exercisable at March 31, 2023		8,500,000	$	0.18		8.0	$	1,579,108
Granted		-		-		-		-
Forfeited		-		-		-		-
Outstanding and exercisable at June 30, 2023		8,500,000	$	0.18		7.7	$	1,579,108

During the three and six months ended ~~March~~June 3130, 2024, the Company granted options to purchase 0 and 8,085,081 shares of common stock of the Company, respectively with an exercise price of $0.05 per share. These options had a total fair value of $634,560. Of these shares, 5,056,800 vest immediately and expire on January 1, 2029, 2,500,000 vest on January 1, 2026, and expire on January 1, 2031, and 528,281 vest on January 1, 2025, and expire on January 1, 2030.

Warrants

A summary of the Company’s warrant activity for the three months ended ~~March~~June 3130, 2024 and 2023, respectively, is as follows:

	Warrant Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Fair Value
Outstanding at December 31, 2023		51,662,689	$	0.45		2.9	$	2,817,424
Outstanding and exercisable at December 31, 2023		51,662,689	$	0.45		2.9	$	2,817,424
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding at March 31, 2024		51,662,689	$	0.45		2.7	$	2,817,424
Outstanding and exercisable at March 31, 2024		51,662,689	$	0.45		2.7	$	2,817,424
Granted		28,747,494		0.06		-		770,218
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding and exercisable at June 30, 2024		80,410,183	$	0.31		3.2	$	3,587,642

	Warrant Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Fair Value
Outstanding at December 31, 2022		73,950,000		$	0.40		1.0	$	1,867,754
Granted		-			-		-		-
Exercised		-			-		-		-
Expired		(15,000,000	)		-		-		-
Outstanding at March 31, 2023		58,950,000		$	0.40		0.9	$	1,867,754

	Warrant Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Fair Value
Outstanding and exercisable at December 31, 2022		73,950,000		$	0.40		1.0	$	1,867,754
Granted		-			-		-		-
Exercised		-			-		-		-
Expired		(15,000,000	)		-		-		-
Outstanding and exercisable at March 31, 2023		58,950,000		$	0.40		0.9	$	1,867,754
Granted		2,540,550			0.25		-		179,026
Exercised		-			-		-		-
Expired		(9,500,000	)		0.40		-		-
Outstanding and exercisable at June 30, 2023		51,990,550		$	0.39		0.9	$	2,046,780

11. Income Taxes

In accordance with ASC 740-270, the Company calculates the interim tax expense based on an annual effective tax rate (“AETR”). The AETR represents the Company’s estimated effective tax rate for the year based on full year projection of tax expense, divided by the projection of full year pretax book loss, adjusted for discrete transactions occurring during the period. The annual effective tax rate for the three months ended ~~March~~June 3130, 2024 , was 0.0%,

12. Commitments & Contingencies

Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.

On December 31, 2023, the Company entered into a net revenue sharing agreement with CRYM Co-Invest in which the Company is obligated to pay royalties equal to 10% of its net revenues. Management determined its best estimate of future expected liability as of ~~March~~June 3130, 2024 , to be $2,~~546~~590,000, which is classified as a contingent royalty liability in long-term liabilities on the Company’s balance sheet.

13. Subsequent Events

On July ~~April 23~~22, 2024, athe ~~holder~~Company ofgave anotice ~~$250,000 promissory note agreed~~ to ~~cancel~~terminate ~~the~~its ~~note~~agreement ~~and~~with ~~accrued interest in exchange for 7~~RubberRock,~~647,494~~ ~~common shares and 7,647,494 warrants exercisable at $0~~Inc.~~07 per share for four years.~~

On July ~~May 9~~25, 2024, ~~Cryomass entered into an Equipment Purchase And Sale Agreement wherein CRYM Co-Invest Unit #2 LLP (“CRYM2”), a special purpose vehicle created for~~ the ~~purpose, agreed~~European toPatent ~~purchase~~office ~~one~~issued ~~CryoSift Separator Unit for $1.2 million. In turn, CRYM2 entered into~~ a ~~lease~~certificate ~~agreement with a wholly-owned US subsidiary~~ of ~~Leef~~registration ~~Brands Inc of Vancouver, Canada to lease the CryoSift Separator~~ for ~~three~~unitary ~~years~~patent ~~with~~protection ~~one three-year options to renew. To date, a substantial portion~~ of the ~~proceeds~~Company’s ofwholy owned ~~the~~subsidiary’s ~~sale~~European ~~have~~patent ~~been received from CRYM2~~EP3634639.

On June 11, 2024, the Company entered into equity subscription agreements with two private investors for $500,000. Per terms of the agreement, upon receipt of proceeds, the Company will issue 8,000,000 shares of common stock, 12,500,000 common stock purchase warrants at an exercise price of $0.06, and 4,500,000 common stock purchase warrants at an exercise price of $0.0001 per share.

On June 12, 2024, an investor invested C$150,700 for 2,750,000 common shares and 2,750,000 five-year warrants exercisable at $0.06 per share.

On June 13, 2024, an investor invested C$100,010 for 1,825,000 common shares and 1,825,000 five-year warrants exercisable at $0.06 per share. That same investor also surrendered a promissory note with accrued interest totaling C$116,450 in exchange for 2,125,000 common shares and 2,125,000 five-year warrants exercisable at $0.06 per share.

On June 13, 2024, a consultant to the Company forgave $50,000 in unpaid consulting fees in exchange for 1,250,000 common shares and 1,250,000 five-year warrants exercisable at $0.06 per share.

On June 13, 2024, an investor invested $26,000 for 650,000 common shares and 650,000 five-year warrants exercisable at $0.06 per share.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

In this quarterly report, unless otherwise specified, our financial statements are expressed in United States Dollars (US$) and are prepared in accordance with United States generally accepted accounting principles. All references to “common shares” refer to the common shares in our capital stock.

Unless expressly indicated or the context requires otherwise, the terms “Cryomass Technologies,” the “Company,” “we,” “us,” and “our” refer to Cryomass Technologies Inc., a Nevada corporation, and, where appropriate, its wholly owned subsidiaries.

General Overview

History

Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) began as Auto Tool Technologies Inc., which was incorporated under the laws of the State of Nevada on May 10, 2011. The Company’s name was changed to AFC Building Technologies Inc. effective January 10, 2014. Effective April 26, 2018, the Company changed its name to First Colombia Development Corp. On ~~May 10, 2018, the Company began to establish various business ventures in Colombia through its Colombian subsidiary, First Colombia Devco S.A.S (“Devco”). On~~ July 1, 2019, the Company ~~acquired~~ acquired 100% of the membership interests in General Extract, LLC, a Colorado limited liability company~~, in exchange for the shares of Devco~~. The name of this subsidiary was subsequently changed to Cryomass LLC. On July 15, 2019, the Company entered into a Membership Interest Purchase Agreement to acquire cannabis-related intellectual property and certain other assets, but not cannabis licenses, of Critical Mass Industries LLC (“CMI”), a Colorado limited liability company. Effective October 14, 2019, the Company changed its name to Redwood Green Corp. InEffective ~~August~~September 1, 2020, the Company ~~established~~changed aits ~~wholly~~name ~~owned~~to ~~Colombian subsidiary,~~ Andina Gold ~~Colombia SAS for this purpose acquiring gold properties in Colombia~~Corp. ~~Effective~~On ~~September~~July 115, ~~2020~~2021, the Company changed its name to ~~Andina~~Cryomass ~~Gold~~Technologies ~~Corp.~~Inc and Insubsequently Q1changed ~~2022~~its ~~the~~trading ~~respective subsidiary~~symbol ~~was~~to ~~closed~~CRYM.

OnThe Company’s ~~July~~principal ~~15,~~office ~~2021,~~is ~~the~~located ~~Company~~at ~~changed~~1001 ~~its~~Bannock ~~name to~~St., ~~Cryomass~~Suite ~~Technologies~~612, ~~Inc~~Denver, ~~and~~CO ~~subsequently~~80204, ~~changed~~and its ~~trading~~telephone ~~symbol~~number tois ~~CRYM~~303-416-7208. The ~~Effective~~Company’s ~~December~~website ~~31,~~is ~~2021,~~www.cryomass.com. ~~the~~Information ~~Company~~appearing ~~disposed~~on ~~of all~~the ~~CMI-related~~website ~~assets~~is ~~and~~not ~~extinguished~~incorporated ~~any~~by ~~and~~reference ~~all~~into ~~related~~this ~~obligations~~report.

17On June 22, 2021, the Company acquired patented technology from CryoCann USA Corp (“Cryocann”) (including US patent #10,864,525) to harness liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, Cryomass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™). Much like sugar and flour refinements, the resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass. For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs. Properly stored, CryoSift™ prevents potency and terpene degradation, preserving value. For processors, the minimized input volume also enables considerable cost savings and logistics advantages. Extracting from CryoSift™ using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise. Cryomass anticipates its efficiencies will catalyze industry-wide shifts in cannabis and hemp post-harvest methods. Additionally, the technology shows promise for diverse trichome-rich plants.

OnThrough an ~~June~~independent ~~22,~~engineering ~~2021,~~and manufacturing firm we refined the ~~Company~~design ~~entered~~of ~~into~~the ~~an Asset~~CryoSift ~~Purchase~~Separator™ ~~Agreement~~for ~~with~~the ~~Cryocann~~handling ~~USA~~of ~~Corp~~harvested hemp, acannabis ~~California~~and ~~corporation~~other ~~(“Cryocann”),~~premium ~~pursuant~~crops. toOur ~~which~~first ~~Company~~CryoSift ~~acquired~~Separator™ unit has been fully developed and delivered to a licensee ~~substantially~~in ~~all~~California as described in the ~~assets~~following section of ~~Cryocann~~this report. The engineering and manufacturing firm has indicated that it has the capacity to manufacture sufficient units to meet our needs for the foreseeable future.

~~The patented technology acquired from CryoCann~~Canadian ~~(including~~Patent USno. ~~patent~~3 ~~#10,864,525)~~064 ~~harnesses~~896 ~~liquid~~“Cryogenic ~~nitrogen~~Separation toof ~~reduce~~Plant ~~biomass~~Material” ~~and~~was ~~then~~filed ~~efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building~~ on ~~this~~May ~~technology~~25, ~~Cryomass~~2018 ~~has~~by ~~engineered its~~two ~~premier Trichome Separation unit (CryoSift Separator™)~~assignors, ~~optimized~~who ~~via~~assigned ~~patented cryogenic processes to rapidly capture intact~~it, ~~high-value~~among ~~cannabis~~other, ~~and~~various ~~hemp~~other ~~trichomes~~intellectual ~~(CryoSift™).~~property ~~Much like sugar and flour refinements~~rights, ~~the~~to ~~resulting CryoSift™ concentrate is~~ a ~~superior~~wholly ~~product~~owned ~~compared~~subsidiary toof ~~unprocessed~~the ~~biomass.~~Company ~~For~~as ~~cultivators,~~part ~~reducing~~of ~~biomass~~the ~~into~~Cryocann ~~CryoSift™~~June ~~slashes volume up to 80%~~22, ~~dramatically~~2021 ~~lowering storage, handling, and transportation costs~~transaction. ~~Properly~~The ~~stored,~~respective ~~CryoSift™~~Canadian ~~prevents~~patent ~~potency~~was ~~and~~granted ~~terpene~~on ~~degradation~~April 19, ~~preserving~~ ~~value~~2022. ~~For~~Provided ~~processors,~~that ~~the~~all ~~minimized~~patent ~~input~~maintenance ~~volume~~fees ~~also~~are ~~enables~~paid, ~~considerable cost savings and logistics advantages. Extracting~~the ~~from~~Canadian ~~CryoSift™~~patent ~~using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise~~no. ~~Cryoass anticipates~~3 ~~its~~064 ~~efficiencies~~896 will ~~catalyze~~expire ~~industry-wide~~on ~~shifts~~May ~~in cannabis and hemp post-harvest methods. Additionally~~25, ~~the technology shows promise for diverse trichome-rich plants~~2038.

~~Through~~In September an2021, ~~independent~~we ~~engineering~~were ~~and~~granted ~~manufacturing firm~~an weadditional ~~refined~~patent ~~the~~for ~~design~~our ofprocess from the ~~CryoSift~~Chinese ~~Separator™~~Intellectual ~~for~~Property ~~the~~Office. ~~handling~~On ofFebruary ~~harvested~~8, ~~hemp~~2024, we ~~cannabis~~were ~~and~~notified ~~other~~by ~~premium~~the ~~crops.~~European ~~Our first~~Patent ~~CryoSift~~Office ~~Separator™~~of ~~unit~~the ~~has~~intention ~~been~~to ~~fully~~grant ~~developed~~a ~~and~~European ~~delivered~~patent tobased aon ~~licensee~~our inapplication ~~California~~no. as18 ~~described~~730 ~~in the following~~941.4-1101. ~~section~~We ofcurrently ~~this~~are ~~report.~~taking ~~The~~steps ~~engineering~~to ~~and~~gain ~~manufacturing~~further ~~firm~~protection ~~has~~for ~~indicated~~our ~~that~~intellectual itproperty ~~has~~through the ~~capacity~~European toUnion ~~manufacture~~Intellectual ~~sufficient units~~Property toOffice, ~~meet~~European ~~our~~Patent ~~needs~~Office ~~for~~and ~~the~~in ~~foreseeable~~several ~~future~~other non-US jurisdictions.

~~Canadian Patent no. 3 064 896 “Cryogenic~~Our ~~Separation~~Current of Plant Material” was filed on May 25, 2018 by two assignors, who assigned it, among other, various other intellectual property rights, to a wholly owned subsidiary of the Company as part of the Cryocann June 22, 2021 transaction. The respective Canadian patent was granted on April 19, 2022. Provided that all patent maintenance fees are paid, the Canadian patent no. 3 064 896 will expire on May 25, 2038.Business

~~In September 2021, we were granted an additional~~Our ~~patent~~business ~~for~~portfolio ~~our~~includes ~~process from~~ the ~~Chinese~~accounts ~~Intellectual~~of ~~Property~~Cryomass ~~Office. On February 8~~LLC, ~~2024,~~Cryomass weCalifornia ~~were~~LLC ~~notified~~and by1304740 ~~the~~BC ~~European~~ULC ~~Patent~~dba ~~Office of~~Cryomass ~~the~~Canada, ~~intention~~which ~~to grant a European patent based on our application no. 18 730 941.4-1101. We currently~~ are ~~taking steps to gain further~~100% ~~protection~~owned ~~for~~by ~~our~~Cryomass ~~intellectual~~Technologies ~~property through the European Union Intellectual Property Office, European Patent Office and in several other non-US jurisdictions~~Inc.

~~Our~~Cryomass Technologies ~~Current~~Inc. ~~Business~~develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The Company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, Cryomass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™). Much like sugar and flour refinements, the resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass. For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs. Properly stored, CryoSift™ prevents potency and terpene degradation, preserving value. For processors, the minimized input volume also enables considerable cost savings and logistics advantages. Extracting from CryoSift™ using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise. Cryomass anticipates its efficiencies will catalyze industry-wide shifts in cannabis and hemp post-harvest methods. Additionally, the technology shows promise for diverse trichome-rich plants.

~~Our~~Because the ~~business~~trichomes ~~portfolio~~collected ~~includes~~with Cryomass technology represent only 10% to 20% of a plant’s volume, they are cheaper to ship and store than gross plant material. For the ~~accounts~~same reason and because trichomes are free of the waxes and other unwanted materials ~~Cryomass~~found ~~LLC~~in the rest of the plant, ~~Cryomass~~processing ~~California~~trichomes ~~LLC~~into oils and ~~1304740~~extracts BCcan ~~ULC~~be ~~dba~~far ~~Cryomass~~quicker, cheaper and ~~Canada~~easier than processing gross plant material. Even trichomes captured from dried or frozen plant parts deliver this cost-saving advantage to processors of oils and extracts. The three-dimensional advantage achievable with the CryoSift Separator™ – first-stage cost savings, product ~~which~~enhancement ~~are~~and ~~100%~~downstream ~~owned~~cost bysavings ~~Cryomass~~– ~~Technologies~~can ~~Inc~~significantly increase a crop’s wholesale value.

~~Cryomass Technologies Inc. develops and licenses~~Production ~~cutting-edge equipment~~ and ~~processes~~processing toof ~~refine harvested cannabis,~~ hemp, and ~~other~~cannabis ~~premium~~is ~~crops.~~a ~~The Company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate~~huge, ~~collect~~worldwide ~~and~~industry. ~~preserve~~In ~~delicate~~the ~~resin glands (trichomes) containing prized compounds like cannabinoids and terpenes~~U.S., ~~Building~~for ~~on this technology~~example, ~~Cryomass~~the ~~has~~wholesale ~~engineered~~value ~~its~~of ~~premier~~the ~~Trichome~~cannabis ~~Separation~~crop ~~unit~~from ~~(CryoSift~~just ~~Separator™),~~the ~~optimized~~11 ~~via~~states ~~patented~~permitting ~~cryogenic processes to rapidly capture intact, high~~adult-~~value~~use ~~cannabis~~ and ~~hemp~~medical ~~trichomes (CryoSift™).~~cannabis ~~Much~~exceeds ~~like~~$6 ~~sugar~~billion ~~and~~annually. ~~flour~~Growth in ~~refinements,~~ the ~~resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass~~U. ~~For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs~~S. ~~Properly stored, CryoSift™ prevents potency~~ and ~~terpene~~in ~~degradation,~~the ~~preserving value. For processors,~~worldwide ~~the~~market ~~minimized~~is ~~input~~likely ~~volume~~fed ~~also~~in ~~enables~~part ~~considerable~~by ~~cost~~the ~~savings~~growing ~~and~~acceptance ~~logistics~~of ~~advantages.~~medicinal ~~Extracting~~cannabis ~~from~~products ~~CryoSift™ using solvents~~ and ~~manufacturing~~anticipated ~~solventless~~legislative ~~products~~changes ~~unlocks~~in ~~industrial scale yields unattainable otherwise. Cryomass anticipates its efficiencies will~~various ~~catalyze~~jurisdictions ~~industry-wide shifts in cannabis and hemp post-harvest methods~~worldwide. ~~Additionally, the technology shows promise for diverse trichome-rich plants.~~

~~Because the trichomes collected with Cryomass technology~~Several ~~represent~~other ~~only~~high-value ~~10% to 20% of a plant’s volume~~plants, ~~they~~including ~~are~~species ~~cheaper~~that ~~to ship and store than gross plant material. For the same reason and because trichomes~~ are ~~free~~important offor ~~the~~health ~~waxes~~ and ~~other~~wellness ~~unwanted materials found in the rest of the plant~~products, ~~processing~~wrap ~~trichomes~~their ~~into~~valuable ~~oils and~~elements ~~extracts~~in ~~can be far quicker, cheaper and easier than processing gross plant material. Even~~ trichomes ~~captured from dried or frozen plant parts deliver this cost-saving advantage to processors of oils and extracts~~. The ~~three-dimensional~~technology ~~advantage~~we ~~achievable with~~are ~~the CryoSift~~developing ~~Separator™~~for –hemp ~~first-stage cost savings, product enhancement~~ and ~~downstream~~cannabis ~~cost~~may ~~savings~~have –profitable ~~can significantly~~application ~~increase~~to athose ~~crop’s~~other ~~wholesale~~species ~~value~~as well.

~~Production~~In January ~~and~~2023, ~~processing~~we ofsigned ~~hemp and cannabis is~~ a ~~huge,~~license ~~worldwide~~and ~~industry.~~lease Inarrangement ~~the~~with ~~U.S.,~~RedTape ~~for~~Core ~~example,~~Partners ~~the~~LLC ~~wholesale~~(“RedTape”) ~~value~~to ofdeploy ~~the~~multiple ~~cannabis~~Cryomass trichome ~~crop~~separation ~~from~~units ~~just~~at the 11prospective ~~states~~partner’s ~~permitting~~facility ~~adult-use and~~in ~~medical~~California ~~cannabis~~and ~~exceeds~~other $6locations, ~~billion~~which ~~annually.~~was ~~Growth in~~amended ~~the~~August U16, 2023.S. ~~and~~No infunds ~~the~~were ~~worldwide~~ever ~~market~~paid isby ~~likely~~RedTape ~~fed~~to inCryomass ~~part~~pursuant byto the ~~growing acceptance~~lease ofand ~~medicinal~~license ~~cannabis~~agreement, ~~products~~ and ~~anticipated~~the ~~legislative~~agreement ~~changes~~was interminated ~~various~~on December ~~jurisdictions~~20, ~~worldwide~~2023.

~~Several~~On August ~~other~~18, ~~high-value~~2023, ~~plants~~the Company entered into a Patent License and Equipment Rental Agreement with RubberRock, ~~including~~Inc. ~~species~~(“RubberRock”) ~~that~~for ~~are~~a ~~important~~term ~~for~~of ~~health~~five years, in which the Company licenses its proprietary CryoSift Separator™ process and ~~wellness~~technology ~~products,~~and ~~wrap~~leases ~~their~~one CryoSift ~~valuable~~Separator™ ~~elements~~Unit for use in ~~trichomes~~the state of California. The ~~technology~~agreement wewas ~~are~~subsequently ~~developing~~amended ~~for~~on ~~hemp~~January 9, 2024 and again on February 28, 2024. Under the terms of the transaction, RubberRock paid license fees of $100,000 payable and ~~cannabis~~a ~~may~~monthly ~~have~~royalty ~~profitable~~based on ~~application~~10% of revenues. Subsequent to ~~those~~the ~~other~~commencement ~~species~~of asthe ~~well~~RubberRock agreement, our Chief Executive Officer, Christian Noel, joined the board of directors of RubberRock at the end of September 2023, which created a related party disclosure requirement. In January 2024, Christian Noel ceased to be on the board of directors of RubberRock. On July 22, 2024, the Company gave notice to terminate its agreement with RubberRock, due to non-compliance with material terms of the Patent License and Equipment Rental Agreement.

InOn February ~~January~~29, ~~2023~~2024, weCryomass ~~signed~~entered ainto ~~license~~an ~~and~~Equipment ~~lease arrangement~~Purchase ~~with~~And ~~RedTape~~Sale ~~Core~~Agreement ~~Partners~~wherein ~~LLC~~CRYM Co-Invest Unit #1 LLP (“~~RedTape~~CRYM1”), a special purpose vehicle created for the purpose, agreed to ~~deploy~~purchase ~~multiple~~one ~~Cryomass~~CryoSift ~~trichome~~Separator ~~separation~~Unit ~~units~~for atC$1.62 ~~the~~million. ~~prospective~~In turn, CRYM1 ~~partner’s~~entered ~~facility~~into ina ~~California~~lease ~~and~~agreement ~~other~~with ~~locations,~~Vmax ~~which~~Canna ~~was~~Solutions ~~amended~~Inc ~~August~~of 16Ontario, ~~2023.~~Canada Noto ~~funds~~lease ~~were~~the ~~ever~~CryoSift ~~paid~~Separator byfor ~~RedTape~~three toyears ~~Cryomass~~with ~~pursuant~~two toone-year ~~the~~options. ~~lease~~To ~~and~~date, ~~license~~some ~~agreement,~~but ~~and~~not ~~the~~all ~~agreement~~of ~~was~~the ~~terminated~~funds onhave ~~December~~been ~~20,~~received ~~2023~~from CRYM1.

On May ~~August 18~~9, ~~2023~~2024, ~~the~~Cryomass ~~Company~~ entered into ~~a Patent~~an ~~License~~Equipment ~~and~~Purchase ~~Equipment~~And ~~Rental~~Sale Agreement ~~with~~wherein ~~RubberRock,~~CRYM ~~Inc.~~Co-Invest Unit #2 LLP (“~~RubberRock~~CRYM2”) ~~for~~ , a ~~term~~special ofpurpose ~~five~~vehicle ~~years,~~created infor ~~which~~ the ~~Company~~ ~~licenses~~purpose, ~~its~~agreed ~~proprietary~~to ~~CryoSift~~purchase ~~Separator™ process and technology and leases~~ one CryoSift Separator™ Unit for ~~use in~~$1.2 ~~the state of California~~million. ~~The~~In ~~agreement was subsequently amended on January 9~~turn, ~~2024~~CRYM2 ~~and again on February 28, 2024. Under the terms~~entered ofinto ~~the~~a ~~transaction,~~lease ~~RubberRock~~agreement ~~paid~~with ~~license fees of $100,000 payable and~~ a ~~monthly~~wholly-owned ~~royalty~~US ~~based~~subsidiary ~~on 10%~~ of ~~revenues.~~Leef ~~Subsequent~~Brands toInc ~~the commencement~~ of ~~the RubberRock agreement~~Vancouver, ~~our~~Canada ~~Chief~~to ~~Executive~~lease ~~Officer, Christian Noel, joined~~ the ~~board~~CryoSift ofSeparator ~~directors of RubberRock at~~for ~~the~~three ~~end~~years ofwith ~~September~~one ~~2023,~~three-year ~~which~~options ~~created~~to ~~a related party disclosure requirement~~renew. InTo ~~January 2024~~date, ~~Christian~~a ~~Noel~~substantial ~~ceased~~portion toof bethe onproceeds of the ~~board of~~sale ~~directors~~have ofbeen ~~RubberRock~~received from CRYM2.

We believe that our technologies will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for largescale cultivators and processors of hemp and cannabis. To that end, Cryomass is working with an extensive pipeline of cultivators and processors in various markets, including several states in the USA, as well as Canada.

19Results of Operations for the Three Months Ended June 30, 2024 and 2023

~~Results~~Our operating ofresults ~~Operations~~ for the ~~Three~~three ~~Months~~months ~~Ended~~ended ~~March~~June 3130, 2024 and 2023 are summarized as follows:

Our operating results for the three months ended March 31, 2024 and 2023 are summarized as follows:

	For the Three Months Ended June 30,						Change
	2024			2023			Dollars			Percentage
Revenues	$	13,889		$	-			13,889			100	%
Cost of goods sold		-			-			-			-
Gross profit		13,889			-			13,889			100	%
Total operating expenses		1,110,762			6,274,718			(5,163,956	)		-82	%
Loss from operations		(1,096,873	)		(6,274,718	)		5,177,845			83	%
Total other expenses		(522,854	)		(87,088	)		(435,766	)		500	%
Net loss before taxes		(1,619,727	)		(6,361,806	)		4,742,079			-75	%
Income taxes		-			-			-			0	%
Net loss	$	(1,619,727	)	$	(6,361,806	)	$	4,742,079			-75	%

	For the Three Months Ended March 31,						Change
	2024			2023			Dollars			Percentage
Revenues	$	5,300		$	-			5,300			100	%
Cost of goods sold		-			-			-			-
Gross profit		5,300			-			5,300			100	%
Total operating expenses		1,056,773			1,531,555			(474,782	)		-31	%
Loss from operations		(1,051,473	)		(1,531,555	)		480,082			-31	%
Total other expenses		(1,502,996	)		(66,971	)		(1,436,025	)		2,144	%
Net loss before taxes		(2,554,469	)		(1,598,526	)		(955,943	)		60	%
Income taxes		-			-			-			0	%
Net loss	$	(2,554,469	)	$	(1,598,526	)	$	(955,943	)		60	%

Revenues

There were $513,~~300~~889 and $0 in revenues for the three months ended ~~March~~June 3130, 2024 and 2023, respectively.

Operating Expenses

Operating expenses encompass personnel costs, research and development, general and administrative expenses, depreciation and amortization expenses, and legal and professional fees. Total operating expenses were $1,~~056~~110,~~773~~762 for the three months ended ~~March~~June 3130, 2024 as compared to $16,~~531~~274,~~555~~ 718 for the three months ended ~~March~~June 3130, 2023. The net decrease of $~~474~~5,~~782~~163,956 or 3182%, is predominantly related to a decrease in general and administrative expense, personnel costs, depreciation and ~~legal~~amortization expense, and ~~professional~~intangible ~~fees~~asset impairment charges in 2023. The decrease in general and administrative expense of $191,301 or 72% predominantly stems from the Company slowing down the use of RSU grants as stock in 2023. The decrease in personnel costs of $161,855 or 57% is predominantly related to executive pay decreases effective at the beginning of fiscal year 2024. ~~Legal~~The decrease in depreciation and ~~professional~~amortization expense of $114,157 or 55% results from the Company ~~fees~~writing ~~also~~off ~~decreased~~all of its acquisition-related intangible assets in the ~~first~~second quarter of ~~2024~~2023. Additionally, the Company fully impaired goodwill and identifiable intangible assets due to ~~larger~~delays ~~audit~~in ~~fees~~implementing ~~related~~our tobusiness ~~the~~model, ~~Company’s~~resulting ~~2022~~in ~~year-end~~a ~~audit~~$4,843,043 ~~that~~impairment ~~were~~charge ~~incurred~~for ~~during~~the Q1three months ended June 30, 2023.

Other Expense

Other expense for the three months ending ~~March 31~~June 30, 2024 consisted of a $1338,~~361,000~~897 loss on ~~contingent~~extinguishment ~~royalty~~of ~~liability~~debt, $~~158~~149,~~634~~787 interest expense – net and $169,~~638~~830 gain on foreign exchange. Other expense for the three months ending ~~March~~June 3130, 2023 consisted of $5382,~~661~~602 interest expense and $134,~~310~~486 loss on foreign exchange. The increase in loss on extinguishment of debt relates to the Company cancelling its debt with two debt holders in exchange for common shares and warrants. The increase in interest expense was a result of the Company issuing promissory notes to investors throughout 2023. The gain on foreign exchange predominantly relates to a payable agreement with Cryomass LLC’s supplier as well as notes denominated in CAD.

Net Loss

For the foregoing reasons, we had a net loss of $21,~~554~~619,~~469~~727 for the three months ending ~~March~~June 3130, 2024, or $0.01 net loss per common share – basic and diluted, compared to a net loss of $16,~~598~~361,~~526~~806 for the three months ending ~~March~~June 3130, 2023, or $0.0103 net loss per common share – basic and diluted.

~~Liquidity,~~Results of ~~Capital~~Operations ~~Resources~~for ~~and~~the ~~Cash~~Six ~~Flows~~Months Ended June 30, 2024 and 2023

~~The Company believes that its available cash balance~~Our asoperating ofresults ~~the date of this filing will not be sufficient to fund its anticipated level of operations~~ for ~~at least~~ the ~~next~~six ~~twelve~~ months~~. The~~ ~~Company~~ended ~~believes~~June ~~that~~30, at2024 ~~the present time, its ability to continue operations depends on cash expected to be available from lease payments~~ and ~~royalty~~2023 ~~payments~~are insummarized ~~connection with future revenue generation,~~ as well as possible debt, equity or other investment sources, to fund its anticipated level of operations for at least the next twelve months. As of March 31, 2024, the Company had a working deficit of $3,330,335 and cash balance of $23,922. The Company estimates that it needs approximately $3,200,000 to cover overhead costs and capital expenditure requirements ranging up to $3,125,000 based on the current pipeline of customer activity. The Company believes that the Company will continue to incur losses for the immediate future. The Company expects to finance future cash needs from the results of operations and additional financing until the Company can achieve profitability and positive cash flows from operating activities. However, there can be no assurance that the Company will receive sufficient cash flow from operations or otherwise that we will be able to attract the necessary financing.follows:

Going Concern

	For the Six Months Ended June 30,						Change
	2024			2023			Dollars			Percentage
Revenues	$	19,189		$	-		$	19,189			100	%
Cost of goods sold		-			-			-			0	%
Gross profit		19,189			-			19,189			100	%
Total operating expenses		2,167,535			7,806,273			(5,638,738	)		-72	%
Loss from operations		(2,148,346	)		(7,806,273	)		5,657,927			72	%
Total other expenses		(2,025,850	)		(154,059	)		(1,871,791	)		1,215	%
Net loss before taxes		(4,174,196	)		(7,960,332	)		3,786,136			48	%
Income taxes		-			-			-			0	%
Net loss	$	(4,174,196	)	$	(7,960,332	)	$	3,786,136			48	%

The Company believes that there is substantial doubt about the Company’s ability to continue as a going concern. Our financial statements for the three months ended March 31, 2024 have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty.Revenues

20There were $19,189 and $0 in revenues for the six months ended June 30, 2024 and 2023, respectively.

~~Capital Resources~~ 20

~~The following table summarizes total current assets, liabilities and~~Operating ~~working (deficit) capital for the periods indicated:~~ Expenses

	March 31, 2024			December 31, 2023
Current assets	$	108,078		$	152,522
Current liabilities		3,438,413			2,493,962
Working (deficit) capital	$	(3,330,355	)	$	2,341,440

Operating expenses encompass personnel costs, research and development, general and administrative expenses, depreciation and amortization expenses, loss on impairment of goodwill, and legal and professional fees. Total operating expenses were $2,167,535 for the six months ended June 30, 2024 as compared to $7,806,273 for the six months ended June 30, 2023. The net decrease of $5,638,738 or 72%, was primarily attributable to a decrease in intangible asset impairment charges, general and administrative, personnel costs, and legal and professional fees. The Company fully impaired goodwill and identifiable intangible assets due to delays in implementing our business model, resulting in a $4,843,043 impairment charge for the six months ended June 30, 2023. The decrease in general and administrative expense of $265,609 or 34% predominantly stems from the Company slowing down the use of RSU grants as stock in 2023. The decrease in personnel costs of $286,118 or 19% is predominantly related to executive pay decreases effective at the beginning of fiscal year 2024. The decrease in depreciation and amortization expense of $208,507 or 78% results from the Company writing off all of its acquisition-related intangible assets in the second quarter of 2023.

~~As of March 31, 2024 and December 31, 2023, we had a cash balance of~~Other ~~$23,922~~Expense ~~and $663,978, respectively.~~

~~Summary~~Other expense for the six months ending June 30, 2024 consisted of $338,897 ~~Cash~~loss ~~Flows~~on extinguishment of debt, $308,421 interest expense – net and $26,468 gain on foreign exchange. Other expense for the six months ending June 30, 2023 consisted of $136,263 interest expense and $17,796 loss on foreign exchange. The increase in loss on extinguishment of debt relates to the Company cancelling its debt with two debt holders in exchange for common shares and warrants. The increase in interest expense was a result of the Company entering into new promissory note agreements during the second quarter of 2023. The gain on foreign exchange predominantly relates to a payable agreement with Cryomass LLC’s supplier.

	For the Three Months Ended March 31,
	2024			2023
Net cash used in operating activities	$	(25,302	)	$	(1,338,343	)
Net cash used in investing activities	$	-		$	(13,736	)
Net cash provided by financing activities	$	-		$	-

Net Loss

~~Net~~For ~~cash~~the ~~used~~foregoing inreasons, ~~operating~~we ~~activities~~had a net loss of $4,174,196 for the six months ending June 30, 2024, or $0.02 net loss per common share – basic and diluted, compared to a net loss of $7,960,332 for the six months ending June 30, 2023, or $0.04 net loss per common share – basic and diluted.

~~Net cash used in operating activities was $25~~Liquidity,~~302~~ ~~during~~Capital ~~the~~Resources three months ended March 31, 2024. This included a net loss of $2,554,469, partially offset by the following: a non-cash charge related to amortization of debt discount of $33,785, a non-cash charge related to depreciation and ~~amortization~~Cash expense of $30,179, a non-cash charge related to gain on foreign exchange of notes payable of $17,933, a non-cash charge related to a loss on contingent royalty liability of $1,361,000, a non-cash charge of accrued principal in-kind interest of $85,860, a non-cash charge related to stock-based compensation for vested RSUs for current period services of $28,226, a non-cash charge related to stock options issued for current period services of $57,557. This was in addition to net changes in prepaid expenses, accounts payable, accounts receivable, and accrued expenses and deferred revenue of $950,493.Flows

~~Net~~The Company believes that its available cash ~~used~~balance inas ~~operating~~of ~~activities~~the ~~was~~date ~~$1,338,343~~of this filing will not be sufficient to fund its anticipated level of ~~during~~operations for at least the ~~three~~next twelve months. ~~ended~~The ~~March~~Company 31believes that, ~~2023.~~at ~~This~~the ~~included~~present atime, ~~net~~its ~~loss~~ability ofto ~~$1,598,526,~~continue aoperations ~~non-~~depends on cash ~~charge~~expected ~~related~~ to ~~depreciation~~be available from lease payments and ~~amortization of~~royalty ~~$124~~payments in connection with future revenue generation,~~529~~ as well as possible debt, aequity ~~non-cash~~or ~~charge~~other ~~related~~investment sources, to ~~stock-based~~fund ~~compensation~~its anticipated level of ~~$62~~operations for at least the next twelve months. As of June 30,~~972~~ 2024, ~~and~~the aCompany ~~non-cash~~had ~~charge~~a ~~related~~working todeficit ~~fair~~of $5,996,694 and ~~value~~cash balance of ~~common~~$497,900. The ~~stock~~Company estimates that ~~issued~~it ~~pursuant~~needs approximately $3,200,000 to ~~service~~cover overhead costs and ~~advisory~~capital ~~agreements~~expenditure ofrequirements ranging up to $653,~~626~~125,000 based on the current pipeline of customer activity. ~~This~~The ~~was~~Company inbelieves ~~addition~~that the Company will continue to ~~net~~incur ~~changes~~losses infor ~~prepaid~~the ~~expenses~~immediate future. The Company expects to finance future cash needs from the results of operations and ~~accounts~~additional ~~payable~~financing until the Company can achieve profitability and ~~accrued~~positive ~~expenses~~cash offlows ~~$(42~~from operating activities. However,~~944)~~ there can be no assurance that the Company will receive sufficient cash flow from operations or otherwise that we will be able to attract the necessary financing.

~~Net cash used in investing activities~~Going Concern

~~There~~The Company ~~was~~believes nothat ~~cash~~there ~~used~~is insubstantial ~~investing~~doubt ~~activities~~about the Company’s ability to continue as a going concern. Our financial statements ~~during~~for the three and six months ended ~~March~~June 3130, 2024 have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty.

~~Net cash used in investing activities was $13,736 during the three months ended March 31, 2023, due to the purchase of intangible assets.~~21

~~Net cash provided by financing activities~~Capital Resources

~~There~~The following ~~was~~table nosummarizes ~~cash~~total ~~activity~~current ~~related~~assets, toliabilities ~~financing activities~~and ~~for~~working ~~the~~(deficit) ~~three~~capital ~~months~~for ~~ended~~the ~~March~~periods ~~31, 2024 and 2023.~~indicated:

	June 30, 2024			December 31, 2023
Current assets	$	533,197		$	152,522
Current liabilities		6,529,891			2,493,962
Working (deficit) capital	$	(5,996,694	)	$	2,341,440

~~Off-Balance~~As of ~~Sheet~~June ~~Arrangements~~30, 2024 and December 31, 2023, we had a cash balance of $497,900 and $663,978, respectively.

~~None.~~Summary of Cash Flows

Critical Accounting Policies

	For the Six Months Ended June 30,
	2024			2023
Net cash used in operating activities	$	(259,475	)	$	(2,337,450	)
Net cash used in investing activities	$	-		$	(49,236	)
Net cash provided by financing activities	$	708,151		$	686,896

~~The discussion and analysis of our financial condition~~Net ~~and~~cash ~~results~~used ~~of operations are based upon our condensed consolidated financial statements, which have been prepared~~ in ~~accordance~~operating with accounting principles generally accepted in the U.S. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangibles, accounting for acquisitions, warrants, income taxes, useful life and recoverability of long-lived assets and deferred income tax asset valuations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.activities

~~Item~~Net 3cash used in operating activities was $259,475 during the six months ended June 30, 2024. ~~Quantitative~~This included a net loss of $4,174,196, partially offset by the following: a non-cash charge related to amortization of debt discount of $73,752, a non-cash charge related to depreciation and ~~Qualitative~~amortization ~~Disclosures~~expense ~~About~~of ~~Market~~$60,358, ~~Risk~~a non-cash charge related to gain on foreign exchange of notes payable of $9,776, a non-cash charge related to a loss on extinguishment of debt of $338,897, a non-cash charge related to a loss on contingent royalty liability of $1,405,000, a non-cash charge of accrued principal in-kind interest of $174,939, a non-cash charge related to stock-based compensation for vested RSUs for current period services of $53,226, a non-cash charge related to stock options issued for current period services of $76,472, and a non-cash charge related to stock and warrants issued for prior period services of $50,000. This was in addition to net changes in prepaid expenses, accounts payable, accounts receivable, and accrued expenses and deferred revenue of $1,691,853.

~~Not~~Net ~~applicable~~cash used in operating activities was $2,337,450 during the six months ended June 30, 2023. This included a net loss of $7,960,332, a non-cash charge related to depreciation and amortization of debt discount of $13,036, a non-cash charge related to depreciation and amortization expense of $268,865, a non-cash charge from a loss on foreign exchange related to notes payable of $1,413, a non-cash charge related to loss on impairment of goodwill and intangible assets of $4,843,043, a non-cash charge related to common stock issued for vested RSUs for current period services of $129,920, a ~~smaller~~non-cash charge ~~reporting~~related ~~company~~to stock-based compensation for common stock issued for current period services of $236,603, a non-cash charge related to common stock issued for current period services of $85,738. This was in addition to net changes in prepaid expenses and accounts payable and accrued expenses of $44,264.

~~Item~~Net cash 4.used ~~Controls~~in ~~and~~investing ~~Procedures~~activities

~~Management’s~~There was ~~Evaluation~~no ofcash ~~Disclosure~~used ~~Controls~~in ~~and~~investing ~~Procedures~~activities during the six months ended June 30, 2024.

~~We have carried out an evaluation of our disclosure~~Net ~~controls~~cash ~~and~~used ~~procedures (as defined~~ in ~~Rules~~investing ~~13a-15(e)~~activities ~~and15d-15(e)~~was ~~under the Exchange Act) that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded~~$49,236 ~~processed,~~during ~~summarized and reported within~~ the ~~time~~six ~~periods~~months ~~specified in~~ended ~~the~~June ~~Securities and Exchange Commission’s rules and forms~~30, ~~and that such information is accumulated and communicated to our management~~2023, ~~including~~ ~~our~~due ~~Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”),~~ to ~~allow~~the ~~timely~~purchase ~~decisions regarding required disclosures. Based upon that evaluation, our Company’s CEO and CFO concluded that our Company’s disclosure controls and procedures were not effective as~~ of ~~March~~intangible ~~31, 2024~~assets.

~~Management has not formally documented its procedures~~Net ~~and~~cash ~~controls~~provided ~~and~~by asfinancing such does not have a sufficient basis to assess its internal controls over financial reporting. Management identified that it did not maintain adequately designed internal control over the preparation and oversight of:activities

●Net cash ~~month-end~~provided by financing activities for the six months ended June 30, 2024 was $708,151, from the Company issuing common stock and warrants ~~period-end~~to ~~financial~~investors ~~close~~as ~~processes~~part of capital raising efforts.

●Net cash ~~non-routine~~provided orby ~~complex~~financing ~~transactions~~activities for the six months ended June 30, 2023 was $686,896, from the Company issuing promissory notes to investors as part of capital raising efforts.

~~● the adoption of new accounting standards.~~22

~~Management’s Report on Internal Control~~Off-Balance ~~Over~~Sheet ~~Financial Reporting~~Arrangements

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024, the end of the period covered by this report and according to the criteria established in Internal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013None.

~~Based on that evaluation, management has concluded~~Critical ~~that~~Accounting the Company did not maintain effective internal control over financial reporting as of the quarter ended March 31, 2024 due to the existence of significant deficiency in the internal control over financial reporting described below.Policies

22The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangibles, accounting for acquisitions, warrants, income taxes, useful life and recoverability of long-lived assets and deferred income tax asset valuations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

~~A significant deficiency is a deficiency, or a~~Item combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis3. AQuantitative ~~material~~and ~~weakness~~Qualitative ~~is a~~Disclosures ~~deficiency~~About orMarket combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.Risk

~~Management identified the following material weakness~~Not ~~during~~applicable ~~the~~for ~~year~~a ~~ended~~smaller ~~December~~reporting ~~31, 2023:~~company.

●Item 4. ~~Management~~Controls ~~did not timely detect impairment of goodwill~~ and ~~intangible assets as of June 30, 2023 in accordance with GAAP.~~Procedures

Management ~~remediated the above material weakness~~’s ~~through~~Evaluation ~~designing~~of ~~processes~~Disclosure toControls ~~timely detect impairment~~ and ~~operating those processes as designed in an effective manner. Further, there is no longer a material risk of detecting goodwill impairment, as the total balance was written off in 2023.~~Procedures

~~Management~~We have ~~has~~carried ~~determined~~out ~~that~~an weevaluation ~~did~~of ~~not~~our ~~maintain effective~~disclosure ~~internal~~ controls ~~over~~and ~~financial~~procedures ~~reporting~~ (as ofdefined in Rules 13a-15(e) and15d-15(e) under the ~~quarter~~Exchange Act) ~~ended~~that ~~March~~are ~~31,~~designed ~~2024~~to ~~due~~ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the ~~existence~~time ofperiods specified in the ~~following~~Securities ~~significant~~and Exchange Commission’s rules and forms, and that such information ~~deficiencies~~is ~~identified~~accumulated byand communicated to our management:, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), to allow timely decisions regarding required disclosures. Based upon that evaluation, our Company’s CEO and CFO concluded that our Company’s disclosure controls and procedures were not effective as of June 30, 2024.

●Management has ~~Due~~not toformally ~~the~~documented ~~Company’s~~its ~~size,~~procedures ~~there~~and iscontrols ~~insufficient~~and ~~segregation~~as ofsuch ~~duties~~does not have a sufficient basis to ~~prevent~~assess orits ~~detect~~internal oncontrols over afinancial ~~timely~~reporting. ~~basis~~Management aidentified ~~misstatement~~that ofit ~~our~~did ~~annual~~not ormaintain ~~interim~~adequately ~~financial~~designed ~~statements.~~internal control over the preparation and oversight of:

● ~~Information~~month-end ~~technology controls are ineffective or lacking, An IT strategic plan~~ and ~~general~~period-end ~~controls~~financial ~~related~~close ~~to access, change management, segregation of duties, contingency planning, information security, business applications, and interfaces are not yet adequately implemented, updated and monitored~~processes.

● ~~A top-down risk assessment has not yet been performed and documented by management to identify, analyze, and assess risks related to operations, external financial and~~ non-~~financial~~routine ~~reporting, internal reporting, compliance, fraud~~ or ~~other~~complex ~~changes that could significantly impact the internal control environment~~transactions.

● Internal controls and related activities that could mitigate financial statement risks within key business processes have either not been established or are not fully adequate, documented, and/or maintained. Also, various regulatory compliance issues currently exist at an entity-level related to the ~~control~~adoption ~~environment component specific to non-performance and/or insufficient/incomplete performance, document maintenance, review and approval, and the enforcement~~ of ~~individual~~new ~~accountability~~accounting standards.

●Management’s Report ~~Documented~~on ~~accounting~~Internal ~~and~~Control ~~other~~Over ~~standard~~Financial rules, guidelines, policies and procedures for key functions within the organization (HR, Payroll, Finance, Sales, IT, etc) have either not been established, are not complete, and/or are not consistently being utilized and monitored against control activities for compliance and ICFR effectiveness.Reporting

23We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024, the end of the period covered by this report and according to the criteria established in Internal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

●Based on Athat ~~whistle-blower~~evaluation, ~~program~~management has concluded that the Company did not ~~yet~~maintain ~~been~~effective ~~established~~internal ~~for~~control ~~the~~over ~~anonymous~~financial reporting, ~~appropriate~~as of ~~tracking,~~the ~~investigating~~quarter ended June 30, ~~monitoring~~2024, ~~and~~due ~~resolving~~to the existence of ~~alleged~~significant ~~wrongdoing,~~deficiency ~~personnel~~in ~~complaints~~the ~~and~~internal ~~grievances,~~control ~~without~~over ~~retribution~~financial reporting described below.

● Recurring, formalized employee communication and training on internal controls and the company’s commitment to ICFR has not yet been established. Additionally, a permanent, independent internal audit solution has not yet been established to perform an ongoing evaluation of the company’s key controls and ICFR, continuous monitoring of corrective actions, and regular reporting of internal control deficiencies and overall effectiveness of the company’s internal control environment.23

WeA significant ~~intend~~deficiency tois ~~continue~~a todeficiency, ~~evaluate~~or ~~and~~a ~~strengthen our~~combination of deficiencies, in internal ~~control~~controls over financial reporting., ~~These~~such ~~efforts~~that ~~require~~there is ~~significant~~a ~~time~~reasonable ~~and~~possibility ~~resources.~~that Ifa wematerial ~~are~~misstatement ~~unable~~of toour ~~establish~~annual ~~adequate internal~~or ~~control~~interim ~~over~~ financial ~~reporting,~~statements wewill ~~may~~not ~~encounter~~be ~~difficulties~~prevented inor ~~the~~detected on ~~audit~~a timely basis. A material weakness is a deficiency or ~~review~~combination of ~~our~~deficiencies ~~financial~~in ~~statements~~internal bycontrol ~~our~~over ~~independent registered~~financial ~~public~~reporting, ~~accounting~~such that ~~firm,~~there ~~which~~is ina ~~turn~~reasonable ~~may~~possibility ~~have~~that a material ~~adverse~~misstatement ~~effect~~of onthe ~~our~~company’s ~~ability~~annual toor ~~prepare~~interim financial statements inwill ~~accordance~~not ~~with~~be ~~GAAP~~prevented ~~and~~or todetected ~~comply~~on ~~with~~a ~~our~~timely ~~SEC reporting obligations~~basis.

Management ~~engaged the services of an experienced~~ ~~expert~~identified ~~in internal controls until September 30, 2023 who evaluated our current system and began implementation of a more effective system to ensure that information required to be disclosed in~~ the ~~reports~~following ~~that~~material weweakness ~~file~~during ~~or submit under~~ the ~~Exchange~~year ~~Act~~ended ~~have~~December ~~been recorded~~31, processed, summarized and reported accurately. Our management intends to develop or improve procedures to address the current significant deficiencies to the extent possible during the next twelve months.2023:

● Management ~~utilizes~~did ~~external~~not ~~experts~~timely todetect ~~assist the~~impairment ~~Company~~of ~~with~~goodwill ~~technical~~and ~~accounting~~intangible ~~expertise~~assets ~~needs~~ as ~~deemed necessary and has engaged a consultant to perform a formal assessment and remediation~~ of ~~its~~June ~~internal~~30, ~~control’s framework. However~~2023, ~~no assurance can be made at this point that the implementation of such controls and procedures will be completed~~ in aaccordance ~~timely~~with ~~manner or that they will be adequate once implemented~~GAAP.

~~Attestation~~Management remediated ~~report~~the above material weakness through designing processes to timely detect impairment and operating those processes as designed in an effective manner. Further, there is no longer a material risk of ~~Registered~~detecting ~~Public~~goodwill impairment, as the total balance was written ~~Accounting~~off ~~Firm~~in 2023.

~~This~~Management has ~~Quarterly~~determined ~~Report~~that onwe ~~Form~~did ~~10-Q does~~ not ~~include an~~maintain ~~attestation~~effective ~~report of our independent registered public accounting firm regarding~~ internal ~~control~~controls over financial reporting ~~because we~~as ~~are~~of ~~not~~the anquarter ~~“accelerated~~ended ~~filer”~~June or30, a2024, ~~“large accelerated filer”. Our management’s report was not subject~~due to ~~attestation~~the byexistence ~~our independent registered public accounting firm pursuant to rules~~ of the ~~SEC~~following ~~that~~significant ~~permit~~deficiencies usidentified toby ~~provide only~~ management~~’s report in this Quarterly Report on Form 10-Q.~~:

~~Management~~● Due to the Company’s ~~Evaluation~~size, there is insufficient segregation of ~~Disclosure Controls~~duties ~~and~~to ~~Procedures~~prevent or detect on a timely basis a misstatement of our annual or interim financial statements.

~~The~~● ~~Company~~Information ~~maintains~~technology ~~disclosure~~ controls ~~and procedures that~~ are ~~designed~~ineffective toor ~~ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934~~lacking, asAn ~~amended,~~IT isstrategic ~~recorded,~~plan ~~processed, summarized~~ and ~~reported~~general ~~within~~controls ~~the~~related ~~time~~to ~~periods specified in the SEC’s rules and forms~~access, ~~and~~ ~~that~~change ~~such information is accumulated and communicated to our~~ management, ~~including~~segregation our chief executive officer (who is also the Company’s principal executive officer), and our chief financial officer (who is also the Company’s principal financial and accounting officer) to allow for timely decisions regarding required disclosure. Thus, in accordance with Rules 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of ~~our management~~duties, ~~including~~contingency ~~our chief executive officer and chief financial officer~~planning, ofinformation ~~the effectiveness of our disclosure controls and procedures as of March 31~~security, ~~2024,~~business ~~which is the end of the period covered by this Form 10-Q. Based on the evaluation of these disclosure controls and procedures~~applications, and ininterfaces ~~light~~are ofnot ~~the~~yet ~~significant~~adequately ~~deficiencies found in our internal controls over financial reporting~~implemented, ~~our~~updated ~~chief executive officer~~ and ~~chief financial officer concluded that our disclosure controls and procedures were not effective~~monitored. ~~The ineffectiveness of our disclosure controls and procedures was due to significant deficiencies identified in our internal control over financial reporting.~~

~~Changes~~● inA ~~Internal~~top-down ~~Control~~risk ~~over~~assessment ~~Financial Reporting~~has not yet been performed and documented by management to identify, analyze, and assess risks related to operations, external financial and non-financial reporting, internal reporting, compliance, fraud or other changes that could significantly impact the internal control environment.

We● ~~have~~Internal ~~not~~controls ~~been~~and ~~able~~related toactivities ~~remediate~~that ~~the~~could ~~significant deficiencies~~mitigate ~~described~~financial instatement ~~our~~risks ~~Annual~~within ~~Report~~key onbusiness ~~Form~~processes ~~10-K~~have ~~for~~either ~~the~~not ~~fiscal~~been ~~year~~established ~~ended~~or ~~December~~are 31not fully adequate, ~~2023~~documented, and/or ~~2022~~maintained. ~~Our~~Also, ~~remediation~~various ~~efforts will~~regulatory ~~continue~~compliance toissues becurrently ~~implemented~~exist ~~throughout~~at ~~our~~an ~~2024~~entity-level ~~fiscal~~related ~~year.~~to ~~We believe that~~ the ~~controls that we will be implementing will improve the effectiveness of our internal~~ control ~~over~~environment ~~financial~~component ~~reporting.~~specific ~~As we continue~~ to ~~evaluate~~non-performance and/or ~~work~~insufficient/incomplete toperformance, ~~improve~~document ~~our~~maintenance, ~~internal~~review ~~control over~~and ~~financial reporting~~approval, weand ~~may determine to take additional measures to address~~ the ~~significant~~enforcement ~~deficiencies or determine to supplement or modify certain~~ of ~~the~~individual ~~remediation measures described above~~accountability.

24● Documented accounting and other standard rules, guidelines, policies and procedures for key functions within the organization (HR, Payroll, Finance, Sales, IT, etc) have either not been established, are not complete, and/or are not consistently being utilized and monitored against control activities for compliance and ICFR effectiveness.

~~PART II – OTHER INFORMATION~~24

~~Item~~● 1.A ~~Legal~~whistle-blower ~~Proceedings~~program has not yet been established for the anonymous reporting, appropriate tracking, investigating, monitoring, and resolving of alleged wrongdoing, personnel complaints and grievances, without retribution.

~~None~~● Recurring, formalized employee communication and training on internal controls and the company’s commitment to ICFR has not yet been established. Additionally, a permanent, independent internal audit solution has not yet been established to perform an ongoing evaluation of the company’s key controls and ICFR, continuous monitoring of corrective actions, and regular reporting of internal control deficiencies and overall effectiveness of the company’s internal control environment.

~~Item~~We intend 1Ato continue to evaluate and strengthen our internal control over financial reporting. ~~Risk~~These ~~Factors~~efforts require significant time and resources. If we are unable to establish adequate internal control over financial reporting, we may encounter difficulties in the audit or review of our financial statements by our independent registered public accounting firm, which in turn may have a material adverse effect on our ability to prepare financial statements in accordance with GAAP and to comply with our SEC reporting obligations.

InManagement engaged ~~addition~~the toservices ~~the~~of ~~other~~an ~~information~~experienced ~~set~~expert ~~forth~~ in ~~this~~internal ~~Report~~controls until September 30, ~~you~~2023 ~~should~~who ~~carefully~~evaluated ~~consider~~our ~~the~~current ~~factors~~system ~~discussed~~and inbegan implementation ~~Item~~of ~~1A,~~a ~~“Risk~~more ~~Factors”~~effective system to ensure that information required to be disclosed in the ~~Company’s~~reports ~~Annual Report~~that onwe ~~Form~~file ~~10-K~~or ~~for~~submit under the ~~year~~Exchange ~~ended~~Act ~~December~~have 31been recorded, ~~2023~~processed, summarized and ~~subsequent~~reported ~~quarterly~~accurately. ~~reports~~Our onmanagement ~~Form~~intends ~~10-Q,~~to ~~which~~develop ~~could~~or ~~materially~~improve ~~affect~~procedures ~~our~~to ~~business,~~address ~~financial~~the ~~condition~~current orsignificant ~~future~~deficiencies ~~results~~to the extent possible during the next twelve months.

~~Item~~Management utilizes 2external experts to assist the Company with technical accounting expertise needs as deemed necessary and has engaged a consultant to perform a formal assessment and remediation of its internal control’s framework. ~~Unregistered~~However, ~~Sales~~no assurance can be made at this point that the implementation of ~~Equity~~such ~~Securities~~controls and ~~Use~~procedures ofwill ~~Proceeds~~be completed in a timely manner or that they will be adequate once implemented.

~~None.~~Attestation report of Registered Public Accounting Firm

~~Item~~This Quarterly 3Report on Form 10-Q does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting because we are not an “accelerated filer” or a “large accelerated filer”. ~~Defaults~~Our management’s ~~Upon~~report ~~Senior~~was ~~Securities~~not subject to attestation by our independent registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s report in this Quarterly Report on Form 10-Q.

~~None.~~Management’s Evaluation of Disclosure Controls and Procedures

~~Item~~The Company 4maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (who is also the Company’s principal executive officer), and our chief financial officer (who is also the Company’s principal financial and accounting officer) to allow for timely decisions regarding required disclosure. ~~Mine~~Thus, ~~Safety~~in accordance ~~Disclosures~~with Rules 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2024, which is the end of the period covered by this Form 10-Q. Based on the evaluation of these disclosure controls and procedures, and in light of the significant deficiencies found in our internal controls over financial reporting, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective. The ineffectiveness of our disclosure controls and procedures was due to significant deficiencies identified in our internal control over financial reporting.

~~Not~~Changes in ~~applicable.~~Internal Control over Financial Reporting

~~Item~~We have 5not been able to remediate the significant deficiencies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and 2022. ~~Other~~Our ~~Information~~remediation efforts will continue to be implemented throughout our 2024 fiscal year. We believe that the controls that we will be implementing will improve the effectiveness of our internal control over financial reporting. As we continue to evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address the significant deficiencies or determine to supplement or modify certain of the remediation measures described above.

~~None.~~25

25PART II – OTHER INFORMATION

Item 6 1. ~~Exhibits~~Legal Proceedings

Exhibit Number		Description
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer.
31.2*		Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer.
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer.
32.2*		Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

None.

*Item 1A. ~~Filed~~Risk ~~herewith.~~Factors

26In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Item 1A, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q, which could materially affect our business, financial condition or future results.

~~SIGNATURES~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorizedNone.

~~CRYOMASS TECHNOLOGIES INC~~Item 3. ~~(Registrant)~~Defaults ~~Dated:~~Upon ~~June~~Senior 28, 2024 /s/ Christian Noel Christian Noel Chief Executive Officer and Director (Principal Executive Officer) Dated: June 28, 2024 /s/ Philip Mullin Philip Mullin Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)Securities

27None.

Item 04.00 0.01 203523079 204021504 false --12-31 Q1 0001533030 true NONE None 0001533030 2024-01-01 2024-03-31 0001533030 2024-06-26 0001533030 2024-03-31 0001533030 2023-12-31 0001533030 us-gaap:RelatedPartyMember 2024-03-31 0001533030 us-gaap:RelatedPartyMember 2023-12-31 0001533030 2023-01-01 2023-03-31 0001533030 us-gaap:CommonStockMember 2022-12-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533030 crym:CommonStockToBeIssuedMember 2022-12-31 0001533030 us-gaap:RetainedEarningsMember 2022-12-31 0001533030 2022-12-31 0001533030 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533030 crym:CommonStockToBeIssuedMember 2023-01-01 2023-03-31 0001533030 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533030 us-gaap:CommonStockMember 2023-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533030 crym:CommonStockToBeIssuedMember 2023-03-31 0001533030 us-gaap:RetainedEarningsMember 2023-03-31 0001533030 2023-03-31 0001533030 us-gaap:CommonStockMember 2023-12-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533030 crym:CommonStockToBeIssuedMember 2023-12-31 0001533030 us-gaap:RetainedEarningsMember 2023-12-31 0001533030 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533030 crym:CommonStockToBeIssuedMember 2024-01-01 2024-03-31 0001533030 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533030 us-gaap:CommonStockMember 2024-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533030 crym:CommonStockToBeIssuedMember 2024-03-31 0001533030 us-gaap:RetainedEarningsMember 2024-03-31 0001533030 srt:MaximumMember 2024-01-01 2024-03-31 0001533030 srt:MinimumMember 2024-01-01 2024-03-31 0001533030 2022-09-15 0001533030 2022-09-15 2022-09-15 0001533030 2023-12-22 0001533030 us-gaap:WarrantMember 2024-03-31 0001533030 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-03-31 0001533030 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-03-31 0001533030 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-03-31 0001533030 crym:ShareBasedPaymentArrangementTrancheFourMember 2024-03-31 0001533030 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533030 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001533030 us-gaap:PatentsMember 2024-03-31 0001533030 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-31 0001533030 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0001533030 crym:RubberRockIncMember 2023-09-23 2023-09-23 0001533030 crym:RubberRockIncMember 2024-01-01 2024-03-31 0001533030 crym:RubberRockIncMember 2024-03-31 0001533030 2023-01-01 2023-12-31 0001533030 crym:InternalUseSoftwaresMember 2024-03-31 0001533030 crym:PatentMember 2023-12-31 0001533030 crym:InternalUseSoftwaresMember 2023-12-31 0001533030 crym:InprocessResearchAndDevelopmentMember 2023-12-31 0001533030 2023-08-18 2023-08-18 0001533030 2023-09-25 2023-09-25 0001533030 2023-01-01 2023-09-30 0001533030 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001533030 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2024-05-09 2024-05-09 0001533030 srt:BoardOfDirectorsChairmanMember 2024-03-31 0001533030 srt:MinimumMember crym:PromissoryNoteMember 2024-01-01 2024-03-31 0001533030 srt:MaximumMember crym:PromissoryNoteMember 2024-01-01 2024-03-31 0001533030 crym:PromissoryNoteMember 2024-03-31 0001533030 crym:PromissoryNoteMember 2024-01-01 2024-03-31 0001533030 srt:MaximumMember us-gaap:WarrantMember 2024-03-31 0001533030 srt:MinimumMember us-gaap:WarrantMember 2024-03-31 0001533030 crym:CRYMCoInvestMember 2022-09-15 0001533030 us-gaap:MeasurementInputSharePriceMember 2024-03-31 0001533030 us-gaap:MeasurementInputExpectedTermMember 2024-03-31 0001533030 us-gaap:MeasurementInputOptionVolatilityMember 2024-03-31 0001533030 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001533030 crym:CRYMCoInvestMember 2024-01-01 2024-03-31 0001533030 crym:SimonLangelierMember 2024-01-01 2024-03-31 0001533030 crym:HealthDiplomatsPteLtdMember 2024-01-01 2024-03-31 0001533030 crym:MarioGobboMember 2024-01-01 2024-03-31 0001533030 crym:AccruedInterestMember 2024-01-01 2024-03-31 0001533030 crym:SimonLangelierMember 2024-03-31 0001533030 crym:HealthDiplomatsPteLtdMember 2024-03-31 0001533030 crym:MarioGobboMember 2024-03-31 0001533030 us-gaap:WarrantMember 2024-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533030 srt:ScenarioForecastMember 2026-01-01 0001533030 srt:ScenarioForecastMember 2026-01-01 2026-01-01 0001533030 srt:ScenarioForecastMember 2025-01-01 0001533030 srt:ScenarioForecastMember 2025-01-01 2025-01-01 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001533030 2023-12-31 2023-12-31 0001533030 2022-12-31 2022-12-31 0001533030 us-gaap:WarrantMember 2023-12-31 0001533030 us-gaap:WarrantMember 2023-12-31 2023-12-31 0001533030 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533030 us-gaap:WarrantMember 2022-12-31 0001533030 us-gaap:WarrantMember 2022-12-31 2022-12-31 0001533030 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001533030 us-gaap:WarrantMember 2023-03-31 0001533030 2024-04-23 0001533030 2024-04-23 2024-04-23 0001533030 us-gaap:SubsequentEventMember 2024-05-09 2024-05-09 0001533030 2024-06-11 0001533030 crym:PurchaseWarrantsMember 2024-06-11 0001533030 2024-06-12 2024-06-12 0001533030 2024-06-12 0001533030 2024-06-13 2024-06-13 0001533030 2024-06-13 0001533030 us-gaap:CommonStockMember 2024-06-13 0001533030 srt:ScenarioForecastMember 2024-06-13 2024-06-13 0001533030 srt:ScenarioForecastMember 2024-06-13 0001533030 srt:ScenarioForecastMember us-gaap:CommonStockMember 2024-06-13 0001533030 crym:PurchaseWarrantsMember 2024-06-13 2024-06-13 0001533030 crym:PurchaseWarrantsMember 2024-06-13 0001533030 crym:PurchaseWarrantsMember us-gaap:CommonStockMember 2024-06-13 0001533030 srt:ScenarioForecastMember crym:PurchaseWarrantsMember 2024-06-13 2024-06-13 0001533030 srt:ScenarioForecastMember crym:PurchaseWarrantsMember 2024-06-13 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CAD Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number		Description
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer.
31.2*		Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer.
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer.
32.2*		Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Filed herewith.

SIGNATURES

CRYOMASS TECHNOLOGIES INC.
(Registrant)

Dated: August 14, 2024

/s/ Christian Noel
Christian Noel
Chief Executive Officer and Director
(Principal Executive Officer)

Dated: August 14, 2024

/s/ Philip Mullin
Philip Mullin
Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)

0.01 0.02 0.03 0.04 204881096 205232785 215196374 220446289 false --12-31 Q2 0001533030 true NONE None 0001533030 2024-01-01 2024-06-30 0001533030 2024-08-13 0001533030 2024-06-30 0001533030 2023-12-31 0001533030 us-gaap:RelatedPartyMember 2024-06-30 0001533030 us-gaap:RelatedPartyMember 2023-12-31 0001533030 2024-04-01 2024-06-30 0001533030 2023-04-01 2023-06-30 0001533030 2023-01-01 2023-06-30 0001533030 us-gaap:CommonStockMember 2022-12-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533030 crym:CommonStockToBeIssuedMember 2022-12-31 0001533030 us-gaap:RetainedEarningsMember 2022-12-31 0001533030 2022-12-31 0001533030 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533030 crym:CommonStockToBeIssuedMember 2023-01-01 2023-03-31 0001533030 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533030 2023-01-01 2023-03-31 0001533030 us-gaap:CommonStockMember 2023-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533030 crym:CommonStockToBeIssuedMember 2023-03-31 0001533030 us-gaap:RetainedEarningsMember 2023-03-31 0001533030 2023-03-31 0001533030 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533030 crym:CommonStockToBeIssuedMember 2023-04-01 2023-06-30 0001533030 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533030 us-gaap:CommonStockMember 2023-06-30 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533030 crym:CommonStockToBeIssuedMember 2023-06-30 0001533030 us-gaap:RetainedEarningsMember 2023-06-30 0001533030 2023-06-30 0001533030 us-gaap:CommonStockMember 2023-12-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533030 crym:CommonStockToBeIssuedMember 2023-12-31 0001533030 us-gaap:RetainedEarningsMember 2023-12-31 0001533030 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533030 crym:CommonStockToBeIssuedMember 2024-01-01 2024-03-31 0001533030 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533030 2024-01-01 2024-03-31 0001533030 us-gaap:CommonStockMember 2024-03-31 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533030 crym:CommonStockToBeIssuedMember 2024-03-31 0001533030 us-gaap:RetainedEarningsMember 2024-03-31 0001533030 2024-03-31 0001533030 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533030 crym:CommonStockToBeIssuedMember 2024-04-01 2024-06-30 0001533030 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533030 us-gaap:CommonStockMember 2024-06-30 0001533030 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533030 crym:CommonStockToBeIssuedMember 2024-06-30 0001533030 us-gaap:RetainedEarningsMember 2024-06-30 0001533030 srt:MaximumMember 2024-01-01 2024-06-30 0001533030 srt:MinimumMember 2024-01-01 2024-06-30 0001533030 crym:LoanAgreementAndUnsecuredPromissoryNoteMember 2022-09-15 0001533030 crym:LoanAgreementAndUnsecuredPromissoryNoteMember 2022-09-15 2022-09-15 0001533030 2023-12-22 0001533030 crym:LoanAgreementAndUnsecuredPromissoryNoteMember 2024-01-01 2024-06-30 0001533030 us-gaap:WarrantMember 2024-06-30 0001533030 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-06-30 0001533030 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-06-30 0001533030 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-06-30 0001533030 crym:ShareBasedPaymentArrangementTrancheFourMember 2024-06-30 0001533030 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001533030 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001533030 us-gaap:PatentsMember 2024-03-31 0001533030 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-31 0001533030 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0001533030 crym:RubberRockIncMember 2023-09-23 2023-09-23 0001533030 crym:RubberRockIncMember 2024-01-01 2024-06-30 0001533030 crym:RubberRockIncMember 2024-06-30 0001533030 crym:RubberRockIncMember 2024-04-01 2024-06-30 0001533030 2023-01-01 2023-12-31 0001533030 crym:InternalUseSoftwaresMember 2024-06-30 0001533030 us-gaap:PatentsMember 2023-12-31 0001533030 crym:InternalUseSoftwaresMember 2023-12-31 0001533030 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001533030 2023-08-18 2023-08-18 0001533030 2023-09-25 2023-09-25 0001533030 2023-01-01 2023-09-30 0001533030 us-gaap:RelatedPartyMember 2024-03-31 0001533030 srt:BoardOfDirectorsChairmanMember 2024-05-09 2024-05-09 0001533030 srt:BoardOfDirectorsChairmanMember 2024-03-31 0001533030 us-gaap:RelatedPartyMember 2024-06-25 2024-06-25 0001533030 srt:MinimumMember crym:PromissoryNoteMember 2024-01-01 2024-06-30 0001533030 srt:MaximumMember crym:PromissoryNoteMember 2024-01-01 2024-06-30 0001533030 crym:PromissoryNoteMember 2024-06-30 0001533030 crym:PromissoryNoteMember 2024-01-01 2024-06-30 0001533030 srt:MaximumMember us-gaap:WarrantMember 2024-06-30 0001533030 srt:MinimumMember us-gaap:WarrantMember 2024-06-30 0001533030 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0001533030 crym:ConvertibleNoteMember 2024-04-23 2024-04-23 0001533030 crym:ConvertibleNoteMember 2024-04-23 0001533030 us-gaap:WarrantMember 2024-04-23 2024-04-23 0001533030 us-gaap:WarrantMember 2024-04-23 0001533030 crym:ConvertibleNoteMember 2024-06-12 2024-06-12 0001533030 us-gaap:WarrantMember 2024-06-12 2024-06-12 0001533030 us-gaap:WarrantMember 2024-06-12 0001533030 crym:CRYMCoInvestLPMember 2022-09-15 0001533030 crym:CRYMCoInvestLPMember 2022-09-15 0001533030 crym:NotePayableMember 2024-01-01 2024-06-30 0001533030 crym:NotePayableMember 2024-06-30 0001533030 us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001533030 us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001533030 us-gaap:MeasurementInputOptionVolatilityMember 2024-06-30 0001533030 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001533030 crym:CRYMCoInvestMember 2024-01-01 2024-06-30 0001533030 crym:SimonLangelierMember 2023-01-01 2023-06-30 0001533030 crym:HealthDiplomatsPteLtdMember 2023-01-01 2023-06-30 0001533030 crym:MarioGobboMember 2023-01-01 2023-06-30 0001533030 crym:NotePayableMember crym:SimonLangelierMember 2024-01-01 2024-06-30 0001533030 crym:NotePayableOneMember crym:HealthDiplomatsPteLtdMember 2024-01-01 2024-06-30 0001533030 crym:NotePayableTwoMember crym:MarioGobboMember 2024-01-01 2024-06-30 0001533030 us-gaap:WarrantMember crym:SimonLangelierMember 2024-06-30 0001533030 us-gaap:WarrantMember crym:HealthDiplomatsPteLtdMember 2024-06-30 0001533030 us-gaap:WarrantMember crym:MarioGobboMember 2024-06-30 0001533030 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001533030 crym:WarrantOneMember crym:HealthDiplomatsPteLtdMember 2024-06-30 0001533030 crym:WarrantTwoMember crym:MarioGobboMember 2024-06-30 0001533030 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001533030 crym:PriorPeriodServicesMember 2023-01-01 2023-03-31 0001533030 crym:CurrentPeriodServicesMember 2023-01-01 2023-03-31 0001533030 crym:CurrentPeriodServicesMember 2023-01-01 2023-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533030 crym:CurrentPeriodServicesMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533030 crym:PriorPeriodServicesMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533030 crym:ZeroPointZeroNineOneMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointZeroNineOneMember 2023-06-30 0001533030 crym:ZeroPoinZeroNineZeroNineMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPoinZeroNineZeroNineMember 2023-06-30 0001533030 crym:ZeroPointOneThreeNineNineMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointOneThreeNineNineMember 2023-06-30 0001533030 crym:ZeroPointOneThreeNineNineMember 2023-04-01 2023-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointZeroNineEightMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointZeroNineEightMember 2023-06-30 0001533030 crym:ZeroPointNineNineFiveMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointNineNineFiveMember 2023-06-30 0001533030 crym:ZeroPointOneZeroEightEightMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointOneZeroEightEightMember 2023-06-30 0001533030 crym:ZeroPointOneOneFiveMember 2023-04-01 2023-06-30 0001533030 crym:ZeroPointOneOneFiveMember 2023-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001533030 srt:ScenarioForecastMember 2026-01-01 0001533030 srt:ScenarioForecastMember 2026-01-01 2026-01-01 0001533030 srt:ScenarioForecastMember 2025-01-01 0001533030 srt:ScenarioForecastMember 2025-01-01 2025-01-01 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001533030 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001533030 us-gaap:WarrantMember 2023-12-31 0001533030 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533030 us-gaap:WarrantMember 2024-03-31 0001533030 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001533030 us-gaap:WarrantMember 2024-06-30 0001533030 us-gaap:WarrantMember 2022-12-31 0001533030 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001533030 us-gaap:WarrantMember 2023-03-31 0001533030 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001533030 us-gaap:WarrantMember 2023-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:g

Filing Compare · Cryomass Technologies, Inc.